Heterocyclic compound, pharmaceutical composition thereof and use thereof

Abstract

Provided in the present application are a heterocyclic compound, a pharmaceutical composition thereof and the use thereof. Specifically provided in the present application are a compound as represented by formula (I-B), a pharmaceutical composition thereof and the use thereof. The compound of the present invention has a new structure, exhibits a good selectively inhibitory activity against PLK4 and inhibitory activity against cancer cell proliferation, and shows good pharmacokinetic properties and in-vivo efficacy.

Description

Heterocyclic compounds, their pharmaceutical compositions and their applications

[0001] This application claims Chinese patent applications 202510200994X (filed February 21, 2025), 2025104213522 (filed April 3, 2025), 2025105407879 (filed April 25, 2025), 2025106533760 (filed May 20, 2025), 2025106778700 (filed May 23, 2025), 2025107797713 (filed June 11, 2025), and 2025109664646 (filed July 11, 2025). Priority is claimed in the following Chinese patent applications: 2025110826904 (filed August 1, 2025), 2025112346403 (filed August 29, 2025), 2025113261366 (filed September 16, 2025), 2025114924041 (filed October 17, 2025), 2025116130183 (filed November 5, 2025), 2025120005449 (filed December 26, 2025), and 2026101871464 (filed February 9, 2026). The full text of the aforementioned Chinese patent applications is incorporated herein by reference. Technical Field

[0002] This application belongs to the field of pharmaceutical technology, specifically relating to heterocyclic compounds, their stereoisomers, pharmaceutically acceptable salts and pharmaceutical compositions thereof, and their uses. Background Technology

[0003] Polo-like kinases (PLKs) are a class of highly conserved serine / threonine kinases, each possessing a highly homologous serine / threonine kinase domain at its N-terminus and a polo-box domain (PBD) at its C-terminus. This PBD domain regulates PLK kinase activity and is involved in the subcellular dynamic localization of the protein. The PLK family has several members, with four isoforms in the human body: PLK1, PLK2, PLK3, and PLK4. These are crucial in the regulation of various phases of the cell cycle.

[0004] PLK4 was discovered in 1994 and is widely found in eukaryotes. Mouse PLK4 is located on chromosome 13 and has two subtypes, a and b. Human PLK4 is located on chromosome 4q28 and consists of only one protein, 970 amino acids in total, showing high homology to mouse PLK4-a. The amino acid sequence of PLK4 differs significantly from other PLKs; while other PLKs have two tandemly arranged polo boxes in their PBDs, PLK4 has only one polo box.

[0005] Studies have found that PLK4 is primarily expressed in actively dividing tissues and cells. The highest expression level of PLK4 mRNA is observed in the testes, and it is also expressed in tumor cell lines such as HeLa, SKOV-3, Saos-2, and A-431. In normally cyclically circulating cells, PLK4 mRNA levels are not expressed in G0 phase, increase at the end of G1 phase, and continue to rise in S and M phases. After mitosis, it gradually decreases in early G1 phase. Research indicates that this precise regulation is essential for maintaining the integrity of the cell nucleus during cell growth and division.

[0006] PLK4 is one of the main regulators of centriole replication. During replication, its activation promotes the recruitment of microtubules to centrioles, thereby promoting centriole maturation. Habedanck first discovered that overexpression of wild-type PLK4 leads to an increase in the number of centrioles, while insufficient PLK4 expression can cause a decrease in the number of centrioles and abnormal centrosome structure. Abnormalities in centrosome structure and number frequently occur in tumor cells, accompanied by cell division defects and genomic instability. PLK4 has been found to be abnormally expressed in some tumor tissues and cell lines and is regulated by p53, potentially participating in tumorigenesis and development. Therefore, PLK4 is a potential target for tumor-targeted therapy. Thus, developing novel PLK4 kinase inhibitors, enriching the variety of clinical drugs, and improving drug accessibility have significant medical and social value. Summary of the Invention

[0007] The technical problem to be solved by this application is to provide a novel compound with PLK4 kinase inhibitory activity. Furthermore, this application provides a novel compound with PLK4 kinase inhibitory activity that has better pharmacodynamic activity and better safety.

[0008] Specifically, this application provides a compound of formula (IB) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0009] in,

[0010] M1 is selected from N, O, NR1, and CR1; R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0011] M2 is selected from N, CR2, and =O; R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0012] M3 is selected from N, CR3, and =O; R3 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0013] M4 is selected from N and C;

[0014] R4 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, =O, C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1- 6-hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0015] R5 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0016] L is selected from -NR6-, -CR6R6-, and -C(=O)-, and R6 is independently selected from hydrogen, C, etc. 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups and C 3-8 cycloalkyl-O-, wherein the C is said to be cycloalkyl-O-, 3-8 The cycloalkyl group may optionally be substituted with one or more groups selected from the following: hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Hydroxyalkyl and C 1-6 Alkyl groups;

[0017] L1 is selected from NR a CR b and C (=O), where R a Selected from hydrogen and C 1-6 Alkyl, R b Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 1- 6-alkoxy and C 1-6 Halogenated alkyl groups;

[0018] L2 is the key, or, selected from NR c CR d N = CR d CR d =CR d CR c R d -CR c R d O, S and NR c C(=O), where R c Selected from hydrogen, C 1-6 Alkyl, R d Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Halogenated alkyl groups;

[0019] Ring A is selected from C 6-10 Aryl, 5-8 membered heteroaryl, 5-12 membered fused-ring group and 5-12 membered heterocyclic group;

[0020] Ring B does not exist, or it is selected from C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-8 membered heteroaryl, 5-12 membered fused-ring group and 5-12 membered heterocyclic group;

[0021] R7 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, sulfur pentafluoride, and -S(=O)2R. 7a -S(=O)2NR 7a R 7b R 7a S(=O)2NR 7b -、-N=S(=O)R 7a R 7b R 7a N = S(=O)(R) 7b )-、-C(=O)NR 7a R 7b -P(=O)R 7a R7b -P(=O)R 7a NR 7a R 7b C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1- 6-Hydroalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 The alkyl group is substituted with one or more substituents in the cycloalkyl and 3-8 membered heterocycloalkyl groups; wherein R 7a R 7b Each is independently selected from hydrogen, C 1-6 Alkyl, C 3-8 cycloalkyl and C 1-6 Alkyl groups;

[0022] R8 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, sulfur pentafluoride, and -S(=O)2R. 7a -S(=O)2NR 7a R 7b R 7a S(=O)2NR 7b -、-N=S(=O)R7a R 7b R 7a N = S(=O)(R) 7b )-、-C(=O)NR 7a R 7b -C 1-4 Alkyl C(=O)NR 7a R 7b -P(=O)R 7a R 7b -P(=O)R 7a NR 7a R 7b -C(=O)R 7a -C(=O)OR 7a C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 The alkyl group is substituted with one or more substituents in the cycloalkyl and 3-8 membered heterocycloalkyl groups; wherein R 7a R 7bEach is independently selected from hydrogen, C 14 Haloalkyl, C 1-6 Alkyl, C 3-8 Cycloalkyl and 3-8 membered heterocycloalkyl, wherein the C 3- The 8-membered cycloalkyl and 3-8-membered heterocycloalkyl groups may optionally be substituted with one or more groups selected from the following: deuterium, halogen, amino, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Hydroxyalkyl and C 1-4 Alkyl groups;

[0023] Alternatively, two R8 atoms attached to the same carbon atom can cyclize into C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic group; or R8 attached to two adjacent carbon atoms co-cyclizes with the attached atoms to form C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups;

[0024] Alternatively, R1 and R4, together with the atoms they are attached to, form a ring C, which is selected from C. 4-8 Cycloalkyl, 4-8 membered heterocyclic, 5-8 membered heteroaryl and C 6-10 Aryl; ring C can be optionally divided by p R 1a The substituted group; R1a is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or two R atoms attached to the same atom 1a Cycloning to C 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups; or two R groups attached to adjacent atoms 1a The atoms it is connected to together form C 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups;

[0025] m, n, and p are each independently selected from 0, 1, 2, 3, and 4;

[0026] Alternatively, R1 and R2 together with the atoms they are attached to form an optionally substituted ring D, which is selected from 5-6 membered heterocyclic groups and 5-6 membered heteroaryl groups;

[0027] Alternatively, R3 and R6, together with the atoms they are attached to, can form an optionally substituted ring E, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic groups, C 6-10 aryl and 5-8-membered heteroaryl; wherein the ring E is optionally surrounded by one or more R 3a Replaced by, R 3a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 quinone heteroaryl groups;

[0028] or,

[0029] R a or R b R5 and the atoms it is attached to form an optionally substituted ring F, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring F is optionally surrounded by one or more R 4a Replaced by, R 4a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-8 membered heteroaryl; or R attached to the same atom 4a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 cycloalkyl or 3-8 membered heterocyclic groups;

[0030] or,

[0031] R c or R d R5 and the atoms it is attached to form an optionally substituted ring G, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring G is optionally surrounded by one or more R 5a Replaced by, R 5a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-8 quinone heteroaryl and -NR 5aa R 5ab ; or R connected to the same atom 5a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 Cycloalkyl or 3-8 membered heterocyclic groups; wherein, R 5aa and R 5ab Each is independently selected from hydrogen and C. 1-4 alkyl;

[0032] Alternatively, R8 and R5, together with the atoms they are attached to, can form an optionally substituted ring H, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the cyclic H is optionally surrounded by one or more R 6a Replaced by, R 6a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C6-10 Aryl and 5-8 membered heteroaryl; or R attached to the same atom 6a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 cycloalkyl or 3-8 membered heterocyclic groups;

[0033] or,

[0034] R c or R d R3 and the atoms it is attached to form an optionally substituted ring K, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring K is optionally surrounded by one or more R ka Replaced by, R ka Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 aryl and 5-8 membered heteroaryl; or R attached to two adjacent carbon atoms ka The atoms bonded to it together form optionally substituted 5-8 membered heteroaryl groups;

[0035] or,

[0036] R3 and R8, together with the atoms they are attached to, form an optionally substituted ring M, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein ring M is optionally surrounded by one or more R 8a Replaced by, R 8a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or R attached to two adjacent carbon atoms 8a The atoms bonded to it together form optionally substituted 5-8 membered heteroaryl groups;

[0037] or,

[0038] Rings B and L are connected by L3, where L3 is an optionally substituted C. 2-7 alkylene chains, the C 2-7 Any methylene unit in the alkylene chain may be optionally and independently replaced by the following groups: C=C, C≡C, -O-, -S-, -C(O)-, -N(R)-. L3a )- or -Cy1-, where R L3a Each is independently selected from hydrogen and C. 1-4 Alkyl, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl and 3-8 membered heterocyclic groups; Cy1 is independently selected from C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-12 heteroaryl, 5-12 fused-ring group, 5-12 fused-ring group, 5-12 spirocyclic group, 5-12 spirocyclic group, 5-12 bridged-ring group and 5-12 bridged-ring group; C 2-7 Any hydrogen atom in the alkylene chain may optionally be replaced by one or more R atoms. L3b Substituted by the group, R L3b Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2- 6-alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or two R groups attached to the same carbon atom L3b It can be cyclicized into C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl or 3-8-membered heterocyclic group; wherein the C 1-4 Alkyl, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10Aryl, 5-12-membered heteroaryl, 5-12-membered fused-ring, 5-12-membered fused-heterocyclic, 5-12-membered spirocyclic, 5-12-membered spirocyclic, 5-12-membered bridged-ring, 5-12-membered bridged-heterocyclic groups may optionally be substituted with the following groups: deuterium, halogen, amino, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Halogenated alkyl or C 1-4 Alkyl groups;

[0039] or structural unit Selected from

[0040] This application provides a compound of formula (IB) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0041] in,

[0042] M1 is selected from N, O, NR1, and CR1; R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0043] M2 is selected from N, CR2, and =O; R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0044] M3 is selected from N, CR3, and =O; R3 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0045] M4 is selected from N and C;

[0046] R4 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, =O, C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1- 6-hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0047] R5 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0048] L is selected from -NR 6- -CR6R 6- And -C(=O)-, R6 is independently selected from hydrogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Halogenated alkoxy groups;

[0049] L1 is selected from NR a CR b and C (=O), where R a Selected from hydrogen and C 1-6 Alkyl, R b Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 1- 6-alkoxy and C 1-6 Halogenated alkyl groups;

[0050] L2 is the key, or, selected from NR c CR d N = CR d CR d =CR d CR c R d -CR c R d O, S and NR c C(=O), where R c Selected from hydrogen and C 1-6 Alkyl, R d Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Halogenated alkyl groups;

[0051] Ring A is selected from C 6-10 Aryl, 5-8 membered heteroaryl, 5-12 membered fused-ring group and 5-12 membered heterocyclic group;

[0052] Ring B does not exist, or it is selected from C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-8 membered heteroaryl, 5-12 membered fused-ring group and 5-12 membered heterocyclic group;

[0053] R7 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, sulfur pentafluoride, and -S(=O)2R. 7a -S(=O)2NR7a R 7b R 7a S(=O)2NR 7b -、-N=S(=O)R 7a R 7b R 7a N = S(=O)(R) 7b )-、-C(=O)NR 7a R 7b -P(=O)R 7a R 7b -P(=O)R 7a NR 7a R 7b C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1- 6-Hydroalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 The alkyl group is substituted with one or more substituents in the cycloalkyl and 3-8 membered heterocycloalkyl groups; wherein R 7a R 7b Each is independently selected from hydrogen, C 1-6 Alkyl, C3-8 cycloalkyl and C 1-6 Alkyl groups;

[0054] R8 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, sulfur pentafluoride, and -S(=O)2R. 7a -S(=O)2NR 7a R 7b R 7a S(=O)2NR 7b -、-N=S(=O)R 7a R 7b R 7a N = S(=O)(R) 7b )-、-C(=O)NR 7a R 7b -C 1-4 Alkyl C(=O)NR 7a R 7b -P(=O)R 7a R 7b -p(=O)R 7a NR 7a R 7b -C(=O)R 7a -C(=O)OR 7a C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 The alkyl group is substituted with one or more substituents in the cycloalkyl and 3-8 membered heterocycloalkyl groups; wherein R 7a R 7b Each is independently selected from hydrogen, C 1-4 Haloalkyl, C 1-6 Alkyl, C 3-8 Cycloalkyl and 3-8 membered heterocycloalkyl, wherein the C 3- The 8-membered cycloalkyl and 3-8-membered heterocycloalkyl groups may optionally be substituted with one or more groups selected from the following: deuterium, halogen, amino, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Hydroxyalkyl and C 1-4 Alkyl groups;

[0055] Alternatively, two R8 atoms attached to the same carbon atom can cyclize into C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic group; or R8 attached to two adjacent carbon atoms co-cyclizes with the attached atoms to form C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups;

[0056] Alternatively, R1 and R4, together with the atoms they are attached to, form a ring C, which is selected from C. 48 Cycloalkyl, 4-8 membered heterocyclic, 5-8 membered heteroaryl and C 6-10 Aryl; ring C can be optionally divided by p R 1a Replaced; R 1a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or two R atoms attached to the same atom 1a Cycloning to C 3-8 cycloalkyl, C3-8 Cycloalkenyl or 3-8 membered heterocyclic groups; or two R groups attached to adjacent atoms 1a The atoms it is connected to together form C 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups;

[0057] m, n, and p are each independently selected from 0, 1, 2, 3, and 4;

[0058] Alternatively, R1 and R2 together with the atoms they are attached to form an optionally substituted ring D, which is selected from 5-6 membered heterocyclic groups and 5-6 membered heteroaryl groups;

[0059] Alternatively, R3 and R6, together with the atoms they are attached to, can form an optionally substituted ring E, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic groups, C 6-10 aryl and 5-8-membered heteroaryl; wherein the ring E is optionally surrounded by one or more R 3a Replaced by, R 3a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 quinone heteroaryl groups;

[0060] or,

[0061] R a or R b R5 and the atoms it is attached to form an optionally substituted ring F, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring F is optionally surrounded by one or more R 4a Replaced by, R 4a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-8 membered heteroaryl; or R attached to the same atom 4a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 cycloalkyl or 3-8 membered heterocyclic groups;

[0062] or,

[0063] R c or R d R5 and the atoms it is attached to form an optionally substituted ring G, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring G is optionally surrounded by one or more R 5a Replaced by, R 5a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-8 quinone heteroaryl and -NR 5aa R 5ab ; or R connected to the same atom 5a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 Cycloalkyl or 3-8 membered heterocyclic groups; wherein, R 5aa and R 5ab Each is independently selected from hydrogen and C. 1-4 alkyl;

[0064] Alternatively, R8 and R5, together with the atoms they are attached to, can form an optionally substituted ring H, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the cyclic H is optionally surrounded by one or more R 6a Replaced by, R 6a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-8 membered heteroaryl; or R attached to the same atom 6a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 cycloalkyl or 3-8 membered heterocyclic groups;

[0065] or,

[0066] R c or R d R3 and the atoms it is attached to form an optionally substituted ring K, which is selected from C. s-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring K is optionally surrounded by one or more R ka Replaced by, R ka Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 aryl and 5-8 membered heteroaryl; or R attached to two adjacent carbon atoms ka The atoms bonded to it together form optionally substituted 5-8 membered heteroaryl groups;

[0067] or,

[0068] R3 and R8, together with the atoms they are attached to, form an optionally substituted ring M, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein ring M is optionally surrounded by one or more R 8a Replaced by, R 8a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or R attached to two adjacent carbon atoms 8a The atoms bonded to it together form optionally substituted 5-8 membered heteroaryl groups;

[0069] or,

[0070] Rings B and L are connected by L3, where L3 is an optionally substituted C. 2-7 alkylene chains, the C 2-7 Any methylene unit in the alkylene chain may be optionally and independently replaced by the following groups: C=C, C≡C, -O-, -S-, -C(O)-, -N(R)-. L3a )- or -Cy1-, where R L3a Each is independently selected from hydrogen and C. 1-4 Alkyl, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl and 3-8 membered heterocyclic groups; Cy1 is independently selected from C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-12 heteroaryl, 5-12 fused-ring group, 5-12 fused-ring group, 5-12 spirocyclic group, 5-12 spirocyclic group, 5-12 bridged-ring group and 5-12 bridged-ring group; C 2-7 Any hydrogen atom in the alkylene chain may optionally be replaced by one or more R atoms. L3b Substituted by the group, R L3b Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2- 6-alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10aryl and 5-8 membered heteroaryl; or two R groups attached to the same carbon atom L3b It can be cyclicized into C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl or 3-8-membered heterocyclic group; wherein the C 1-4 Alkyl, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-12-membered heteroaryl, 5-12-membered fused-ring, 5-12-membered fused-heterocyclic, 5-12-membered spirocyclic, 5-12-membered spiroheterocyclic, 5-12-membered bridged-ring, and 5-12-membered bridged-ring may optionally be substituted with the following groups: deuterium, halogen, amino, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Halogenated alkyl or C 1-4 Alkyl groups;

[0071] or structural unit Selected from

[0072] This application provides a compound of formula (IB) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0073] in,

[0074] M1 is selected from N, O, NR1, and CR1; R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0075] M2 is selected from N, CR2, and =O; R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl and 5-8 heteroaryl groups are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0076] M3 is selected from N, CR3, and =O; R3 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0077] M4 is selected from N and C;

[0078] R4 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, =O, C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1- 6-hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0079] R5 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0080] L is selected from -NR6-, -CR6R6-, and -C(=O)-, and R6 is independently selected from hydrogen, C, etc. 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Halogenated alkoxy groups;

[0081] L1 is selected from NR a CR b and C (=O), where R a Selected from hydrogen and C 1-6 Alkyl, R b Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 1- 6-alkoxy and C 1-6 Halogenated alkyl groups;

[0082] L2 is the key, or, selected from NR cc CR d N = CR d CR d =CR d CR c R d -CR c R d O, S and NR c C(=O), where R c Selected from hydrogen, C 1-6 Alkyl, R d Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Halogenated alkyl groups;

[0083] Ring A is selected from C 6-10 Aryl, 5-8 membered heteroaryl, 5-12 membered fused-ring group and 5-12 membered heterocyclic group;

[0084] Ring B does not exist, or it is selected from C.3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-8 membered heteroaryl, 5-12 membered fused-ring group and 5-12 membered heterocyclic group;

[0085] R7 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, sulfur pentafluoride, and -S(=O)2R. 7a -S(=O)2NR 7a R 7b R 7a S(=O)2NR 7b -、-N=S(=O)R 7a R 7b R 7a N = S(=O)(R) 7b )-、-C(=O)NR 7a R 7b -P(=O)R 7a R 7b -P(=O)R 7a NR 7a R 7b C 1-6 Alkyl, C2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1- 6-Hydroalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 The alkyl group is substituted with one or more substituents in the cycloalkyl and 3-8 membered heterocycloalkyl groups; wherein R 7a R 7b Each is independently selected from hydrogen, C 1-6 Alkyl, C 3-8 cycloalkyl and C 1-6 Alkyl groups;

[0086] R8 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, sulfur pentafluoride, and -S(=O)2R. 7a -S(=O)2NR 7a R 7b R 7a S(=O)2NR 7b -、-N=S(=O)R 7a R 7b R 7a N = S(=O)(R) 7b )-、-C(=O)NR 7a R 7b -C 1-4 Alkyl C(=O)NR 7a R 7b -P(=O)R 7a R 7b -P(=O)R 7a NR 7a R 7b C 1-6 Alkyl, C 2-6 alkenyl, C 2- 6-acetylinyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 The alkyl group is substituted with one or more substituents in the cycloalkyl and 3-8 membered heterocycloalkyl groups; wherein R 7a R 7b Each is independently selected from hydrogen and C 1-6 alkyl;

[0087] Alternatively, two R8 atoms attached to the same carbon atom can cyclize into C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic group; or R8 attached to two adjacent carbon atoms co-cyclizes with the attached atoms to form C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups;

[0088] Alternatively, R1 and R4, together with the atoms they are attached to, form a ring C, which is selected from C. 4-8 Cycloalkyl, 4-8 membered heterocyclic, 5-8 membered heteroaryl and C 6-10 Aryl; ring C can be optionally divided by p R 1a Replaced; R 1a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or two R atoms attached to the same atom 1a Cycloning to C 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups; or two R groups attached to adjacent atoms 1a The atoms it is connected to together form C3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups;

[0089] m, n, and p are each independently selected from 0, 1, 2, 3, and 4;

[0090] Alternatively, R1 and R2 together with the atoms they are attached to form an optionally substituted ring D, which is selected from 5-6 membered heterocyclic groups and 5-6 membered heteroaryl groups;

[0091] Alternatively, R3 and R6, together with the atoms they are attached to, can form an optionally substituted ring E, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic groups, C 6-10 aryl and 5-8-membered heteroaryl; wherein the ring E is optionally surrounded by one or more R 3a Replaced by, R 3a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 quinone heteroaryl groups;

[0092] or,

[0093] R a or R b R5 and the atoms it is attached to form an optionally substituted ring F, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring F is optionally surrounded by one or more R 4a Replaced by, R 4a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-8 membered heteroaryl; or R attached to the same atom 4a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 cycloalkyl or 3-8 membered heterocyclic groups;

[0094] or,

[0095] R c or R d R5 and the atoms it is attached to form an optionally substituted ring G, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring G is optionally surrounded by one or more R 5a Replaced by, R 5a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-8 quinone heteroaryl and -NR 5aa R 5ab ; or R connected to the same atom 5a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 Cycloalkyl or 3-8 membered heterocyclic groups; wherein, R 5aa and R 5ab Each is independently selected from hydrogen and C. 14 alkyl;

[0096] Alternatively, R8 and R5, together with the atoms they are attached to, can form an optionally substituted ring H, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the cyclic H is optionally surrounded by one or more R 6a Replaced by, R 6a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-8 membered heteroaryl; or R attached to the same atom 6a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 cycloalkyl or 3-8 membered heterocyclic groups;

[0097] or,

[0098] R c or R d R3 and the atoms it is attached to form an optionally substituted ring K, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring K is optionally surrounded by one or more R ka Replaced by, R ka Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 aryl and 5-8 membered heteroaryl; or R attached to two adjacent carbon atoms ka The atoms bonded to it together form optionally substituted 5-8 membered heteroaryl groups;

[0099] or,

[0100] R3 and R8, together with the atoms they are attached to, form an optionally substituted ring M, which is selected from C. s-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein ring M is optionally surrounded by one or more R 8a Replaced by, R 8a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or R attached to two adjacent carbon atoms 8a The atoms bonded to it together form optionally substituted 5-8 membered heteroaryl groups;

[0101] or,

[0102] Rings B and L are connected by L3, where L3 is an optionally substituted C. 2-7 alkylene chains, the C 2-7 Any methylene unit in the alkylene chain may be optionally and independently replaced by the following groups: C=C, C≡C, -O-, -S-, -C(O)-, -N(R)-. L3a )- or -Cy1-, where R L3a Each is independently selected from hydrogen and C. 1-4 Alkyl, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl and 3-8 membered heterocyclic groups; Cy1 is independently selected from C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-12 heteroaryl, 5-12 fused-ring group, 5-12 fused-ring group, 5-12 spirocyclic group, 5-12 spirocyclic group, 5-12 bridged-ring group and 5-12 bridged-ring group; C 2-7 Any hydrogen atom in the alkylene chain may optionally be replaced by one or more R atoms. L3b Substituted by the group, R L3b Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or two R groups attached to the same carbon atom L3b It can be cyclicized into C 3-8 cycloalkyl, C3-8 Cycloalkenyl or 3-8 membered heterocyclic group; wherein the C 1-4 Alkyl, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-12-membered heteroaryl, 5-12-membered fused-ring, 5-12-membered fused-heterocyclic, 5-12-membered spirocyclic, 5-12-membered spirocyclic, 5-12-membered bridged-ring, and 5-12-membered bridged-ring groups may optionally be substituted with the following groups: deuterium, halogen, amino, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Halogenated alkyl or C 1-4 Alkyl groups;

[0103] or structural unit Selected from

[0104] This application provides a compound of formula (IB) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0105] in,

[0106] M1 is selected from N, O, NR1, and CR1; R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0107] M2 is selected from N, CR2, and =O; R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0108] M3 is selected from N, CR3, and =O; R3 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0109] M4 is selected from N and C;

[0110] R4 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, =O, C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1- 6-hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0111] R5 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0112] L is selected from -NR6-, -CR6R6-, and -C(=O)-, and R6 is independently selected from hydrogen, C, etc. 1-6 Alkyl, deuterated C 1-6 Alkyl and C 1-6 Alkyl groups;

[0113] L1 is selected from NR a CR b and C (=O), where R a Selected from hydrogen and C 1-6 Alkyl, R b Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 1- 6-alkoxy and C 1-6 Halogenated alkyl groups;

[0114] L2 is the key, or, selected from NR c CR d N = CR d CR d =CR d CR c R d -CR c R d O, S and NR c C(=O), where R c Selected from hydrogen, C 1-6 Alkyl, R d Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Halogenated alkyl groups;

[0115] Ring A is selected from C 6-10 Aryl, 5-8 membered heteroaryl, 5-12 membered fused-ring group and 5-12 membered heterocyclic group;

[0116] Ring B does not exist, or it is selected from C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-8 membered heteroaryl, 5-12 membered fused-ring group and 5-12 membered heterocyclic group;

[0117] R7 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, sulfur pentafluoride, and -S(=O)2R. 7a -S(=O)2NR 7a R 7b R 7a S(=O)2NR 7b -、-N=S(=O)R 7a R 7b R 7a N = S(=O)(R) 7b )-、-C(=O)NR 7a R 7b -P(=O)R 7a R 7b -P(=O)R 7a NR 7a R 7b C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1- 6-Hydroalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8The alkyl group is substituted with one or more substituents in the cycloalkyl and 3-8 membered heterocycloalkyl groups; wherein R 7a R 7b Each is independently selected from hydrogen, C 1-6 Alkyl, C 3-8 cycloalkyl and C 1-6 Alkyl groups;

[0118] R8 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, sulfur pentafluoride, and -S(=O)2R. 7a -S(=O)2NR 7a R 7b R 7a S(=O)2NR 7b -、-N=S(=O)R 7a R 7b R 7a N = S(=O)(R) 7b )-、-C(=O)NR 7a R 7b -C 1-4 Alkyl C(=O)NR 7a R 7b -P(=O)R 7a R 7b -P(=O)R 7a NR 7a R 7b C 1-6 Alkyl, C 2-6 alkenyl, C 2- 6-acetylinyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10Aryl and 5-8-membered heteroaryl groups may optionally be further converted by deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 The alkyl group is substituted with one or more substituents in the cycloalkyl and 3-8 membered heterocycloalkyl groups; wherein R 7a R 7b Each is independently selected from hydrogen and C 1-6 alkyl;

[0119] Alternatively, two R8 atoms attached to the same carbon atom can cyclize into C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic group; or R8 attached to two adjacent carbon atoms co-cyclizes with the attached atoms to form C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups;

[0120] Alternatively, R1 and R4, together with the atoms they are attached to, form a ring C, which is selected from C. 4-8 Cycloalkyl, 4-8 membered heterocyclic, 5-8 membered heteroaryl and C 6-10 Aryl; ring C can be optionally divided by p R 1a Replaced; R 1a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or two R atoms attached to the same atom 1a Cycloning to C 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups; or two R groups attached to adjacent atoms 1a The atoms it is connected to together form C 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups;

[0121] m, n, and p are each independently selected from 0, 1, 2, 3, and 4;

[0122] Alternatively, R1 and R2 together with the atoms they are attached to form an optionally substituted ring D, which is selected from 5-6 membered heterocyclic groups and 5-6 membered heteroaryl groups;

[0123] Alternatively, R3 and R6, together with the atoms they are attached to, can form an optionally substituted ring E, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic groups, C 6-10 aryl and 5-8-membered heteroaryl; wherein the ring E is optionally surrounded by one or more R 3a Replaced by, R 3a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 quinone heteroaryl groups;

[0124] or,

[0125] R a or R b R5 and the atoms it is attached to form an optionally substituted ring F, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring F is optionally surrounded by one or more R 4a Replaced by, R 4a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-8 membered heteroaryl; or R attached to the same atom4a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 cycloalkyl or 3-8 membered heterocyclic groups;

[0126] or,

[0127] R c or R d R5 and the atoms it is attached to form an optionally substituted ring G, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring G is optionally surrounded by one or more R 5a Replaced by, R 5a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-8 quinone heteroaryl and -NR 5aa R 5ab ; or R connected to the same atom 5a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 Cycloalkyl or 3-8 membered heterocyclic groups; wherein, R 5aa and R 5ab Each is independently selected from hydrogen and C. 1-4 alkyl;

[0128] Alternatively, R8 and R5, together with the atoms they are attached to, can form an optionally substituted ring H, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the cyclic H is optionally surrounded by one or more R 6a Replaced by, R 6a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-8 membered heteroaryl; or R attached to the same atom 6a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 cycloalkyl or 3-8 membered heterocyclic groups;

[0129] or,

[0130] R c or R d R3 and the atoms it is attached to form an optionally substituted ring K, which is selected from C. s-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring K is optionally surrounded by one or more R ka Replaced by, R ka Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 aryl and 5-8 membered heteroaryl; or R attached to two adjacent carbon atoms ka The atoms bonded to it together form optionally substituted 5-8 membered heteroaryl groups;

[0131] or,

[0132] R3 and R8, together with the atoms they are attached to, form an optionally substituted ring M, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein ring M is optionally surrounded by one or more R 8a Replaced by, R 8a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or R attached to two adjacent carbon atoms 8a The atoms bonded to it together form optionally substituted 5-8 membered heteroaryl groups;

[0133] or,

[0134] Rings B and L are connected by L3, where L3 is an optionally substituted C. 2-7 alkylene chains, the C 2-7 Any methylene unit in the alkylene chain may be optionally and independently replaced by the following groups: C=C, C≡C, -O-, -S-, -C(O)-, -N(R)-. L3a )- or -Cyl-, where R L3a Each is independently selected from hydrogen and C. 14 Alkyl, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl and 3-8 membered heterocyclic groups; Cy1 is independently selected from C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-12 heteroaryl, 5-12 fused-ring group, 5-12 fused-ring group, 5-12 spirocyclic group, 5-12 spirocyclic group, 5-12 bridged-ring group and 5-12 bridged-ring group; C 2-7 Any hydrogen atom in the alkylene chain may optionally be replaced by one or more R atoms. L3b Substituted by the group, R L3b Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2- 6-alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or two R groups attached to the same carbon atom L3b It can be cyclicized into C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl or 3-8-membered heterocyclic group; wherein the C 1-4 Alkyl, C 3-8cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-12-membered heteroaryl, 5-12-membered fused-ring, 5-12-membered fused-heterocyclic, 5-12-membered spirocyclic, 5-12-membered spirocyclic, 5-12-membered bridged-ring, and 5-12-membered bridged-ring groups may optionally be substituted with the following groups: deuterium, halogen, amino, hydroxyl, cyano, C 14 Alkyl, C 14 Halogenated alkyl or C 14 Alkyl groups;

[0135] or structural unit Selected from

[0136] This application provides a compound of formula (IB) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0137] in,

[0138] M1 is selected from N, O, NR1, and CR1; R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0139] M2 is selected from N, CR2, and =O; R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0140] M3 is selected from N, CR3, and =O; R3 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0141] M4 is selected from N and C;

[0142] R4 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, =O, C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1- 6-hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0143] R5 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0144] L is selected from -NR6-, -CR6R6-, and -C(=O)-, and R6 is independently selected from hydrogen, C, etc. 1-6 Alkyl, deuterated C 1-6 Alkyl and C 1-6 Alkyl groups;

[0145] L1 is selected from NR a and CR b , where R a Selected from hydrogen, C 1-6 Alkyl, R b Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Halogenated alkyl groups;

[0146] L2 is the key, or, selected from NR c CR d N = CR d CR d =CR d CR c R d -CR c R d , O and S, where R c Selected from hydrogen, C 1-6 Alkyl, R d Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Halogenated alkyl groups;

[0147] Ring A is selected from C 6-10 Aryl, 5-8 membered heteroaryl, 5-12 membered fused-ring group and 5-12 membered heterocyclic group;

[0148] Ring B does not exist, or it is selected from C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-8 membered heteroaryl, 5-12 membered fused-ring group and 5-12 membered heterocyclic group;

[0149] R7 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, sulfur pentafluoride, and -S(=O)2R. 7a -S(=O)2NR 7a R7b R 7a S(=O)2NR 7b -、-N=S(=O)R 7a R 7b R 7a N = S(=O)(R) 7b )-、-C(=O)NR 7a R 7b -P(=O)R 7a R 7b -P(=O)R 7a NR 7a R 7b C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1- 6-Hydroalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8-membered heteroaryl groups may optionally be further converted by deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 The alkyl group is substituted with one or more substituents in the cycloalkyl and 3-8 membered heterocycloalkyl groups; wherein R 7a R 7b Each is independently selected from hydrogen, C 1- 6-alkyl, C 3-8cycloalkyl and C 1-6 Alkyl groups;

[0150] R8 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, sulfur pentafluoride, and -S(=O)2R. 7a -S(=O)2NR 7a R 7b R 7a S(=O)2NR 7b -、-N=S(=O)R 7a R 7b R 7a N = S(=O)(R) 7b )-、-C(=O)NR 7a R 7b -C 1-4 Alkyl C(=O)NR 7a R 7b -P(=O)R 7a R 7b -P(=O)R 7a NR 7a R 7b C 1-6 Alkyl, C 2-6 alkenyl, C 2- 6-acetylinyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 The alkyl group is substituted with one or more substituents in the cycloalkyl and 3-8 membered heterocycloalkyl groups; wherein R 7a R 7b Each is independently selected from hydrogen and C 1-6 alkyl;

[0151] Alternatively, two R8 atoms attached to the same carbon atom can cyclize into C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic group; or R8 attached to two adjacent carbon atoms co-cyclizes with the attached atoms to form C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups;

[0152] Alternatively, R1 and R4, together with the atoms they are attached to, form a ring C, which is selected from C. 4-8 Cycloalkyl, 4-8 membered heterocyclic, 5-8 membered heteroaryl and C 6-10 Aryl; ring C can be optionally divided by p R 1a Replaced; R 1a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or two R atoms attached to the same atom 1a Cycloning to C 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups; or two R groups attached to adjacent atoms 1a The atoms it is connected to together form C 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups;

[0153] m, n, and p are each independently selected from 0, 1, 2, 3, and 4;

[0154] Alternatively, R1 and R2 together with the atoms they are attached to form an optionally substituted ring D, which is selected from 5-6 membered heterocyclic groups and 5-6 membered heteroaryl groups;

[0155] Alternatively, R3 and R6, together with the atoms they are attached to, can form an optionally substituted ring E, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic groups, C 6-10 aryl and 5-8-membered heteroaryl; wherein the ring E is optionally surrounded by one or more R 3a Replaced by, R 3a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 quinone heteroaryl groups;

[0156] or,

[0157] R a or R b R5 and the atoms it is attached to form an optionally substituted ring F, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring F is optionally surrounded by one or more R 4a Replaced by, R 4a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-8 membered heteroaryl; or R attached to the same atom 4a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 cycloalkyl or 3-8 membered heterocyclic groups;

[0158] or,

[0159] R c or R d R5 and the atoms it is attached to form an optionally substituted ring G, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring G is optionally surrounded by one or more R 5a Replaced by, R 5a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-8 quinone heteroaryl and -NR 5aa R 5ab ; or R connected to the same atom 5a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 Cycloalkyl or 3-8 membered heterocyclic groups; wherein, R 5aa and R 5ab Each is independently selected from hydrogen and C. 1-4 alkyl;

[0160] Alternatively, R8 and R5, together with the atoms they are attached to, can form an optionally substituted ring H, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the cyclic H is optionally surrounded by one or more R 6a Replaced by, R 6a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-8 membered heteroaryl; or R attached to the same atom6a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 cycloalkyl or 3-8 membered heterocyclic groups;

[0161] or,

[0162] R c or R d R3 and the atoms it is attached to form an optionally substituted ring K, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring K is optionally surrounded by one or more R ka Replaced by, R ka Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 aryl and 5-8 membered heteroaryl; or R attached to two adjacent carbon atoms ka The atoms bonded to it together form optionally substituted 5-8 membered heteroaryl groups;

[0163] or,

[0164] R3 and R8, together with the atoms they are attached to, form an optionally substituted ring M, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein ring M is optionally surrounded by one or more R 8a Replaced by, R 8a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10aryl and 5-8 membered heteroaryl; or R attached to two adjacent carbon atoms 8a The atoms bonded to it together form optionally substituted 5-8 membered heteroaryl groups;

[0165] or,

[0166] Rings B and L are connected by L3, where L3 is an optionally substituted C. 2-7 alkylene chains, the C 2-7 Any methylene unit in the alkylene chain may be optionally and independently replaced by the following groups: C=C, C≡C, -O-, -S-, -C(O)-, -N(R)-. L3a )- or -Cy1-, where R L3a Each is independently selected from hydrogen and C. 1-4 Alkyl, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl and 3-8 membered heterocyclic groups; Cy1 is independently selected from C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-12 heteroaryl, 5-12 fused-ring group, 5-12 fused-ring group, 5-12 spirocyclic group, 5-12 spirocyclic group, 5-12 bridged-ring group and 5-12 bridged-ring group; C 2-7 Any hydrogen atom in the alkylene chain may optionally be replaced by one or more R atoms. L3b Substituted by the group, R L3b Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2- 6-alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or two R groups attached to the same carbon atom L3b It can be cyclicized into C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl or 3-8-membered heterocyclic group; wherein the C 1-4 Alkyl, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10Aryl, 5-12-membered heteroaryl, 5-12-membered fused-ring, 5-12-membered fused-heterocyclic, 5-12-membered spirocyclic, 5-12-membered spirocyclic, 5-12-membered bridged-ring, and 5-12-membered bridged-ring groups may optionally be substituted with the following groups: deuterium, halogen, amino, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Halogenated alkyl or C 1-4 Alkyl groups;

[0167] or structural unit Selected from

[0168] This application provides a compound of formula (IB) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0169] in,

[0170] M1 is selected from N, O, NR1, and CR1; R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8-membered heteroaryl groups may optionally be further converted by deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0171] M2 is selected from N, CR2, and =O; R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0172] M3 is selected from N, CR3, and =O; R3 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8-membered heteroaryl groups may optionally be further converted by deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0173] M4 is selected from N and C;

[0174] R4 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, =O, C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1- 6-hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0175] R5 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0176] L is selected from -NR6-, -CR6R6-, and C(=O)-, where R6 is independently selected from hydrogen, C, etc. 1-6 Alkyl and C 1-6 Alkyl groups;

[0177] L1 is selected from NR a and CR b , where R a Selected from hydrogen, C 1-6 Alkyl, R b Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Halogenated alkyl groups;

[0178] L2 is the key, or, selected from NR c CR d N = CR d CR d =CR d CR c R d -CR c R d , O and S, where R c Selected from hydrogen, C 1-6 Alkyl, R d Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Halogenated alkyl groups;

[0179] Ring A is selected from C 6-10 Aryl, 5-8 membered heteroaryl, 5-12 membered fused-ring group and 5-12 membered heterocyclic group;

[0180] Ring B does not exist, or it is selected from C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-8 membered heteroaryl, 5-12 membered fused-ring group and 5-12 membered heterocyclic group;

[0181] R7 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, sulfur pentafluoride, and -S(=O)2R. 7a -S(=O)2NR 7a R 7b R 7a S(=O)2NR 7b -、-N=S(=O)R 7a R7b R 7a N = S(=O)(R) 7b )-、-C(=O)NR 7a R 7b -P(=O)R 7a R 7b -P(=O)R 7a NR 7a R 7b C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1- 6-Hydroalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 The alkyl group is substituted with one or more substituents in the cycloalkyl and 3-8 membered heterocycloalkyl groups; wherein R 7a R 7b Each is independently selected from hydrogen, C 1-6 Alkyl, C 3-8 cycloalkyl and C 1-6 Alkyl groups;

[0182] R8 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, sulfur pentafluoride, and -S(=O)2R. 7a -S(=O)2NR 7a R 7b R 7a S(=O)2NR 7b -、-N=S(=O)R 7a R 7b R 7a N = S(=O)(R) 7b )-、-C(=o)NR 7a R 7b -C 1-4 Alkyl C(=O)NR 7a R 7b -P(=O)R 7a R 7b -P(=O)R 7a NR 7a R 7b C 1-6 Alkyl, C 2-6 alkenyl, C 2- 6-acetylinyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C1-6 Halogenated alkoxy groups, C 3-8 The alkyl group is substituted with one or more substituents in the cycloalkyl and 3-8 membered heterocycloalkyl groups; wherein R 7a R 7b Each is independently selected from hydrogen and C 1-6 alkyl;

[0183] Alternatively, two R8 atoms attached to the same carbon atom can cyclize into C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic group; or R8 attached to two adjacent carbon atoms co-cyclizes with the attached atoms to form C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups;

[0184] Alternatively, R1 and R4, together with the atoms they are attached to, form a ring C, which is selected from C. 4-8 Cycloalkyl, 4-8 membered heterocyclic, 5-8 membered heteroaryl and C 6-10 Aryl; ring C can be optionally divided by p R 1a Replaced; R 1a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or two R atoms attached to the same atom 1a Cycloning to C 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups; or two R groups attached to adjacent atoms 1a The atoms it is connected to together form C 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups;

[0185] m, n, and p are each independently selected from 0, 1, 2, 3, and 4;

[0186] Alternatively, R1 and R2 together with the atoms they are attached to form an optionally substituted ring D, which is selected from 5-6 membered heterocyclic groups and 5-6 membered heteroaryl groups;

[0187] Alternatively, R3 and R6, together with the atoms they are attached to, can form an optionally substituted ring E, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic groups, C 6-10 aryl and 5-8-membered heteroaryl; wherein the ring E is optionally surrounded by one or more R 3a Replaced by, R 3a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 quinone heteroaryl groups;

[0188] or,

[0189] R a or R b R5 and the atoms it is attached to form an optionally substituted ring F, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring F is optionally surrounded by one or more R 4a Replaced by, R 4a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-8 membered heteroaryl; or R attached to the same atom 4a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 cycloalkyl or 3-8 membered heterocyclic groups;

[0190] or,

[0191] R c or Rd R5 and the atoms it is attached to form an optionally substituted ring G, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring G is optionally surrounded by one or more R 5a Replaced by, R 5a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-8 membered heteroaryl and NR 5aa R 5ab ; or R connected to the same atom 5a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 Cycloalkyl or 3-8 membered heterocyclic groups; wherein, R 5aa and R 5ab Each is independently selected from hydrogen and C. 14 alkyl;

[0192] Alternatively, R8 and R5, together with the atoms they are attached to, can form an optionally substituted ring H, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the cyclic H is optionally surrounded by one or more R 6a Replaced by, R 6a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-8 membered heteroaryl; or R attached to the same atom 6a It can form optionally substituted C atoms together with the atoms it is attached to.3-8 cycloalkyl or 3-8 membered heterocyclic groups;

[0193] or,

[0194] R c or R d R3 and the atoms it is attached to form an optionally substituted ring K, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring K is optionally surrounded by one or more R ka Replaced by, R ka Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 aryl and 5-8 membered heteroaryl; or R attached to two adjacent carbon atoms ka The atoms bonded to it together form optionally substituted 5-8 membered heteroaryl groups;

[0195] or,

[0196] R3 and R8, together with the atoms they are attached to, form an optionally substituted ring M, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein ring M is optionally surrounded by one or more R 8a Replaced by, R 8a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or R attached to two adjacent carbon atoms 8aThe atoms bonded to it together form optionally substituted 5-8 membered heteroaryl groups;

[0197] or,

[0198] Rings B and L are connected by L3, where L3 is an optionally substituted C. 2-7 alkylene chains, the C 2-7 Any methylene unit in the alkylene chain may be optionally and independently replaced by the following groups: C=C, C≡C, -O-, -S-, -C(O)-, -N(R)-. L3a )- or -Cy1-, where R L3a Each is independently selected from hydrogen and C. 14 Alkyl, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups; Cy1 is independently selected from C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-12 heteroaryl, 5-12 fused-ring group, 5-12 fused-ring group, 5-12 spirocyclic group, 5-12 spirocyclic group, 5-12 bridged-ring group and 5-12 bridged-ring group; C 2-7 Any hydrogen atom in the alkylene chain may optionally be replaced by one or more R atoms. L3b Substituted by the group, R L3b Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2- 6-alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or two R groups attached to the same carbon atom L3b It can be cyclicized into C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl or 3-8-membered heterocyclic group; wherein the C 1-4 Alkyl, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10Aryl, 5-12-membered heteroaryl, 5-12-membered fused-ring, 5-12-membered fused-heterocyclic, 5-12-membered spirocyclic, 5-12-membered spiroheterocyclic, 5-12-membered bridged-ring, and 5-12-membered bridged-ring may optionally be substituted with the following groups: deuterium, halogen, amino, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Halogenated alkyl or C 1-4 Alkyl groups;

[0199] or structural unit Selected from

[0200] This application provides a compound of formula (IB) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0201] in,

[0202] M1 is selected from N, O, NR1, and CR1; R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0203] M2 is selected from N, CR2, and =O; R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0204] M3 is selected from N, CR3, and =O; R3 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0205] M4 is selected from N and C;

[0206] R4 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, =O, C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1- 6-hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0207] R5 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0208] L is selected from -NR6- and -CR6R6-, where R6 is independently selected from hydrogen and C. 1-6 alkyl;

[0209] L1 is selected from NR a and CR b , where R a Selected from hydrogen, C 1-6 Alkyl, R b Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Halogenated alkyl groups;

[0210] L2 is the key, or, selected from NR c CR d N = CR d CR d =CR d CR c R d -CR c R d , O and S, where R c Selected from hydrogen and C 1-6 Alkyl, R d Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Halogenated alkyl groups;

[0211] Ring A is selected from C 6-10 Aryl, 5-8 membered heteroaryl, 5-12 membered fused-ring group and 5-12 membered heterocyclic group;

[0212] Ring B does not exist, or it is selected from C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-8 membered heteroaryl, 5-12 membered fused-ring group and 5-12 membered heterocyclic group;

[0213] R7 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, sulfur pentafluoride, and -S(=O)2R. 7a -S(=O)2NR 7a R 7b R 7a S(=O)2NR 7b -、-N=S(=O)R 7a R 7b R 7aN = S(=O)(R) 7b )-、-C(=O)NR 7a R 7b -P(=O)R 7a R 7b -P(=O)R 7a NR 7a R 7b C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1- 6-Hydroalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 The alkyl group is substituted with one or more substituents in the cycloalkyl and 3-8 membered heterocycloalkyl groups; wherein R 7a R 7b Each is independently selected from hydrogen, C 1-6 Alkyl and C 3-8 cycloalkyl;

[0214] R8 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, sulfur pentafluoride, and -S(=O)2R. 7a -S(=O)2NR 7a R7b R 7a S(=O)2NR 7b -、-N=S(=O)R 7a R 7b R 7a N = S(=O)(R) 7b )-、-C(=O)NR 7a R 7b -C 1-4 Alkyl C(=O)NR 7a R 7b -P(=O)R 7a R 7b -P(=O)R 7a NR 7a R 7b C 1-6 Alkyl, C 2-6 alkenyl, C 2- 6-acetylinyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 The alkyl group is substituted with one or more substituents in the cycloalkyl and 3-8 membered heterocycloalkyl groups; wherein R 7a R7b Each is independently selected from hydrogen and C 1-6 alkyl;

[0215] Alternatively, two R8 atoms attached to the same carbon atom can cyclize into C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic group; or R8 attached to two adjacent carbon atoms co-cyclizes with the attached atoms to form C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups;

[0216] Alternatively, R1 and R4, together with the atoms they are attached to, form a ring C, which is selected from C. 48 Cycloalkyl, 4-8 membered heterocyclic, 5-8 membered heteroaryl and C 6-10 Aryl; ring C can be optionally divided by p R 1a Replaced; R 1a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or two R atoms attached to the same atom 1a Cycloning to C 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups; or two R groups attached to adjacent atoms 1a The atoms it is connected to together form C 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups;

[0217] m, n, and p are each independently selected from 0, 1, 2, 3, and 4;

[0218] Alternatively, R1 and R2 together with the atoms they are attached to form an optionally substituted ring D, which is selected from 5-6 membered heterocyclic groups and 5-6 membered heteroaryl groups;

[0219] Alternatively, R3 and R6, together with the atoms they are attached to, can form an optionally substituted ring E, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic groups, C 6-10aryl and 5-8-membered heteroaryl; wherein the ring E is optionally surrounded by one or more R 3a Replaced by, R 3a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 quinone heteroaryl groups;

[0220] or,

[0221] R a or R b R5 and the atoms it is attached to form an optionally substituted ring F, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring F is optionally surrounded by one or more R 4a Replaced by, R 4a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-8 membered heteroaryl; or R attached to the same atom 4a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 cycloalkyl or 3-8 membered heterocyclic groups;

[0222] or,

[0223] R c or R d R5 and the atoms it is attached to form an optionally substituted ring G, which is selected from C. 5-8 cycloalkyl, C 5-8Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring G is optionally surrounded by one or more R 5a Replaced by, R 5a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-8 quinone heteroaryl and -NR 5aa R 5ab ; or R connected to the same atom 5a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 Cycloalkyl or 3-8 membered heterocyclic groups; wherein, R 5aa and R 5ab Each is independently selected from hydrogen and C. 1-4 alkyl;

[0224] Alternatively, R8 and R5, together with the atoms they are attached to, can form an optionally substituted ring H, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the cyclic H is optionally surrounded by one or more R 6a Replaced by, R 6a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-8 membered heteroaryl; or R attached to the same atom 6a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 cycloalkyl or 3-8 membered heterocyclic groups;

[0225] or,

[0226] R c or R d R3 and the atoms it is attached to form an optionally substituted ring K, which is selected from C. s-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring K is optionally surrounded by one or more R ka Replaced by, R ka Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 aryl and 5-8 membered heteroaryl; or R attached to two adjacent carbon atoms ka The atoms bonded to it together form optionally substituted 5-8 membered heteroaryl groups;

[0227] or,

[0228] R3 and R8, together with the atoms they are attached to, form an optionally substituted ring M, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein ring M is optionally surrounded by one or more R 8a Replaced by, R 8a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or R attached to two adjacent carbon atoms 8a The atoms bonded to it together form optionally substituted 5-8 membered heteroaryl groups;

[0229] or structural unit for

[0230] This application provides a compound of formula (IB) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0231] in,

[0232] M1 is selected from N, O, NR1, and CR1; R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0233] M2 is selected from N, CR2, and =O; R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0234] M3 is selected from N, CR3, and =O; R3 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0235] M4 is selected from N and C;

[0236] R4 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, =O, C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1- 6-hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0237] R5 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0238] L is selected from -NR6- and -CR6R6-, where R6 is independently selected from hydrogen and C. 1-6 alkyl;

[0239] L1 is selected from NR a and CR b , where R a Selected from hydrogen and C1-6 Alkyl, R b Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Halogenated alkyl groups;

[0240] L2 is the key, or, selected from NR c CR d N = CR d CR d =CR d CR c R d -CR c R d , O and S, where R c Selected from hydrogen and C 1-6 Alkyl, R d Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Halogenated alkyl groups;

[0241] Ring A is selected from C 6-10 Aryl, 5-8 membered heteroaryl, 5-12 membered fused-ring group and 5-12 membered heterocyclic group;

[0242] Ring B does not exist, or it is selected from C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-8 membered heteroaryl, 5-12 membered fused-ring group and 5-12 membered heterocyclic group;

[0243] R7 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, sulfur pentafluoride, and -S(=O)2R. 7a -S(=O)2NR 7a R 7b R 7a S(=O)2NR 7b -、-N=S(=O)R 7a R 7b R 7a N = S(=O)(R) 7b )-、-C(=O)NR 7a R 7b -P(=O)R 7a R 7b -P(=O)R 7a NR 7a R 7b C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C1-6 Deuterated alkyl, C 1- 6-Hydroalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 The alkyl group is substituted with one or more substituents in the cycloalkyl and 3-8 membered heterocycloalkyl groups; wherein R 7a R 7b Each is independently selected from hydrogen, C 1-6 Alkyl and C 3-8 cycloalkyl;

[0244] R8 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, sulfur pentafluoride, and -S(=O)2R. 7a -S(=O)2NR 7a R 7b R 7a S(=O)2NR 7b -、-N=S(=O)R 7a R 7b R 7a N = S(=O)(R) 7b )-、-C(=O)NR 7a R 7b -C 1-4 Alkyl C(=O)NR 7a R7b -P(=O)R 7a R 7b -P(=O)R 7a NR 7a R 7b C 1-6 Alkyl, C 2-6 alkenyl, C 2- 6-acetylinyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 The alkyl group is substituted with one or more substituents in the cycloalkyl and 3-8 membered heterocycloalkyl groups; wherein R 7a R 7b Each is independently selected from hydrogen and C 1-6 alkyl;

[0245] Alternatively, two R8 atoms attached to the same carbon atom can cyclize into C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic group; or R8 attached to two adjacent carbon atoms co-cyclizes with the attached atoms to form C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups;

[0246] Alternatively, R1 and R4, together with the atoms they are attached to, form a ring C, which is selected from C. 4-8 Cycloalkyl, 4-8 membered heterocyclic, 5-8 membered heteroaryl and C 6-10 Aryl; ring C can be optionally divided by p R 1a Replaced; R 1a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or two R atoms attached to the same atom 1a Cycloning to C 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups; or two R groups attached to adjacent atoms 1a The atoms it is connected to together form C 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups;

[0247] m, n, and p are each independently selected from 0, 1, 2, 3, and 4;

[0248] Alternatively, R1 and R2 together with the atoms they are attached to form an optionally substituted ring D, which is selected from 5-6 membered heterocyclic groups and 5-6 membered heteroaryl groups;

[0249] Alternatively, R3 and R6, together with the atoms they are attached to, can form an optionally substituted ring E, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic groups, C 6-10 aryl and 5-8-membered heteroaryl; wherein the ring E is optionally surrounded by one or more R 3a Replaced by, R 3a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 quinone heteroaryl groups;

[0250] or,

[0251] R a or R b R5 and the atoms it is attached to form an optionally substituted ring F, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring F is optionally surrounded by one or more R 4a Replaced by, R 4a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-8 membered heteroaryl; or R attached to the same atom 4a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 cycloalkyl or 3-8 membered heterocyclic groups;

[0252] or,

[0253] R c or R d R5 and the atoms it is attached to form an optionally substituted ring G, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring G is optionally surrounded by one or more R 5a Replaced by, R 5a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-8 membered heteroaryl; or R attached to the same atom 5a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 cycloalkyl or 3-8 membered heterocyclic groups;

[0254] Alternatively, R8 and R5, together with the atoms they are attached to, can form an optionally substituted ring H, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the cyclic H is optionally surrounded by one or more R 6a Replaced by, R 6a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-8 membered heteroaryl; or R attached to the same atom 6a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 cycloalkyl or 3-8 membered heterocyclic groups;

[0255] or,

[0256] R c or R d R3 and the atoms it is attached to form an optionally substituted ring K, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring K is optionally surrounded by one or more R ka Replaced by, R ka Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 aryl and 5-8 membered heteroaryl; or R attached to two adjacent carbon atoms ka The atoms bonded to it together form optionally substituted 5-8 membered heteroaryl groups;

[0257] or,

[0258] R3 and R8, together with the atoms they are attached to, form an optionally substituted ring M, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein ring M is optionally surrounded by one or more R 8a Replaced by, R 8a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or R attached to two adjacent carbon atoms 8a The atoms bonded to it together form optionally substituted 5-8 membered heteroaryl groups;

[0259] or structural unit for

[0260] This application provides a compound of formula (IB) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0261] in,

[0262] M1 is selected from N, O, NR1, and CR1; R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0263] M2 is selected from N, CR2, and =O; R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Alkylthio, C 1-6Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0264] M3 is selected from N, CR3, and =O; R3 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0265] M4 is selected from N and C;

[0266] R4 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, =O, C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1- 6-hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0267] R5 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0268] L is selected from -NR6- and -CR6R6-, where R6 is independently selected from hydrogen and C. 1-6 alkyl;

[0269] L1 is selected from NR a and CR b , where R a Selected from hydrogen, C 1-6 Alkyl, R b Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Halogenated alkyl groups;

[0270] L2 is the key, or, selected from NR c CR d N = CR d CR d =CR d and CR c R d -CR c R d , where R c Selected from hydrogen, C 1-6 Alkyl, R dSelected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Halogenated alkyl groups;

[0271] Ring A is selected from C 6-10 Aryl, 5-8 membered heteroaryl, 5-12 membered fused-ring group and 5-12 membered heterocyclic group;

[0272] Ring B does not exist, or it is selected from C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-8 membered heteroaryl, 5-12 membered fused-ring group and 5-12 membered heterocyclic group;

[0273] R 7 Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, sulfur pentafluoride, -S(=O)2R 7a -S(=O)2NR 7a R 7b R 7a S(=O)2NR 7b -、-N=S(=O)R 7a R 7b R 7a N = S(=O)(R) 7b )-、-C(=O)NR 7a R 7b -P(=O)R 7a R 7b -P(=O)R 7a NR 7a R 7b C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1- 6-Hydroalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 The alkyl group is substituted with one or more substituents in the cycloalkyl and 3-8 membered heterocycloalkyl groups; wherein R 7a R 7b Each is independently selected from hydrogen, C 1-6 Alkyl and C 3-8 cycloalkyl;

[0274] R8 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, sulfur pentafluoride, and -S(=O)2R. 7a -S(=o)2NR 7a R 7b R 7a S(=O)2NR 7b -、-N=S(=O)R 7a R 7b R 7a N = S(=O)(R) 7b )-、-C(=O)NR 7a R 7b -C 14 Alkyl C(=O)NR 7a R 7b -P(=O)R 7a R 7b -P(=O)R 7a NR 7a R 7b C 1-6 Alkyl, C 2-6 alkenyl, C 2- 6-acetylinyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 The alkyl group is substituted with one or more substituents in the cycloalkyl and 3-8 membered heterocycloalkyl groups; wherein R 7a R 7b Each is independently selected from hydrogen and C 1-6 alkyl;

[0275] Alternatively, two R8 atoms attached to the same carbon atom can cyclize into C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic group; or R8 attached to two adjacent carbon atoms co-cyclizes with the attached atoms to form C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups;

[0276] Alternatively, R1 and R4, together with the atoms they are attached to, form a ring C, which is selected from C. 4-8 Cycloalkyl, 4-8 membered heterocyclic, 5-8 membered heteroaryl and C 6-10 Aryl; ring C can be optionally divided by p R 1a Replaced; R 1a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or two R atoms attached to the same atom 1a Cycloning to C 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups; or two R groups attached to adjacent atoms 1a The atoms it is connected to together form C 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups;

[0277] m, n, and p are each independently selected from 0, 1, 2, 3, and 4;

[0278] Alternatively, R1 and R2 together with the atoms they are attached to form an optionally substituted ring D, which is selected from 5-6 membered heterocyclic groups and 5-6 membered heteroaryl groups;

[0279] Alternatively, R3 and R6, together with the atoms they are attached to, can form an optionally substituted ring E, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic groups, C 6-10 aryl and 5-8-membered heteroaryl; wherein the ring E is optionally surrounded by one or more R 3a Replaced by, R 3a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 quinone heteroaryl groups;

[0280] or,

[0281] R a or R b R5 and the atoms it is attached to form an optionally substituted ring F, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring F is optionally surrounded by one or more R 4a Replaced by, R 4aSelected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-8 membered heteroaryl; or R attached to the same atom 4a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 cycloalkyl or 3-8 membered heterocyclic groups;

[0282] or,

[0283] R c or R d R5 and the atoms it is attached to form an optionally substituted ring G, which is selected from C. s-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring G is optionally surrounded by one or more R 5a Replaced by, R 5a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-8 membered heteroaryl; or R attached to the same atom 5a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 cycloalkyl or 3-8 membered heterocyclic groups;

[0284] Alternatively, R8 and R5, together with the atoms they are attached to, can form an optionally substituted ring H, which is selected from C. s-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the cyclic H is optionally surrounded by one or more R 6a Replaced by, R6a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-8 membered heteroaryl; or R attached to the same atom 6a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 cycloalkyl or 3-8 membered heterocyclic groups;

[0285] or,

[0286] R c or R d R3 and the atoms it is attached to form an optionally substituted ring K, which is selected from C. s-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring K is optionally surrounded by one or more R ka Replaced by, R ka Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 aryl and 5-8 membered heteroaryl; or R attached to two adjacent carbon atoms ka The atoms bonded to it together form optionally substituted 5-8 membered heteroaryl groups;

[0287] or,

[0288] R3 and R8, together with the atoms they are attached to, form an optionally substituted ring M, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein ring M is optionally surrounded by one or more R8a Replaced by, R 8a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or R attached to two adjacent carbon atoms 8a The atoms bonded to it together form optionally substituted 5-8 membered heteroaryl groups;

[0289] or structural unit for

[0290] This application provides a compound of formula (IA) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0291] in,

[0292] M1 is selected from N, O, NR1, and CR1; R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0293] M2 is selected from N and CR2; R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0294] M3 is selected from N and CR3; R3 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0295] R4 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, =O, C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1- 6-hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0296] R5 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0297] L is selected from -NR6- and -CR6R6-, where R6 is independently selected from hydrogen and C. 1-6 alkyl;

[0298] L1 is selected from NR a and C Rb , where R a Selected from hydrogen and C 1-6 Alkyl, R b Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Halogenated alkyl groups;

[0299] L2 is the key, or, selected from NR c CR d N = CR d CR d =CR d and CR c R d -CR c R d , where R c Selected from hydrogen, C 1-6 Alkyl, R d Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Halogenated alkyl groups;

[0300] Ring A is selected from C 6-10 Aryl, 5-8 membered heteroaryl, 5-12 membered fused-ring group and 5-12 membered heterocyclic group;

[0301] Ring B does not exist, or it is selected from C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-8 membered heteroaryl, 5-12 membered fused-ring group and 5-12 membered heterocyclic group;

[0302] R7 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, sulfur pentafluoride, and -S(=O)2R.7a -S(=O)2NR 7a R 7b R 7a S(=O)2NR 7b -、-N=S(=O)R 7a R 7b R 7a N = S(=O)(R) 7b )-、-C(=O)NR 7a R 7b -P(=O)R 7a R 7b -P(=O)R 7a NR 7a R 7b C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1- 6-Hydroalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 The alkyl group is substituted with one or more substituents in the cycloalkyl and 3-8 membered heterocycloalkyl groups; wherein R 7a R 7bEach is independently selected from hydrogen and C 1-6 alkyl;

[0303] R8 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, sulfur pentafluoride, and -S(=O)2R. 7a -S(=O)2NR 7a R 7b R 7a S(=O)2NR 7b -、-N=S(=O)R 7a R 7b R 7a N = S(=O)(R) 7b )-、-C(=O)NR 7a R 7b -C 1-4 Alkyl C(=O)NR 7a R 7b -P(=O)R 7a R 7b -P(=O)R 7a NR 7a R 7b C 1-6 Alkyl, C 2-6 alkenyl, C 2- 6-acetylinyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 The alkyl group is substituted with one or more substituents in the cycloalkyl and 3-8 membered heterocycloalkyl groups; wherein R 7a R 7b Each is independently selected from hydrogen and C 1-6 alkyl;

[0304] Alternatively, two R8 atoms attached to the same carbon atom can cyclize into C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic group; or R8 attached to two adjacent carbon atoms co-cyclizes with the attached atoms to form C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups;

[0305] Alternatively, R1 and R4, together with the atoms they are attached to, form a ring C, which is selected from C. 4-8 Cycloalkyl, 4-8 membered heterocyclic, 5-8 membered heteroaryl and C 6-10 Aryl; ring C can be optionally divided by p R 1a Replaced; R 1a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or two R atoms attached to the same atom 1a Cycloning to C 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups; or two R groups attached to adjacent atoms 1a The atoms it is connected to together form C 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups;

[0306] m, n, and p are each independently selected from 0, 1, 2, 3, and 4;

[0307] Alternatively, R1 and R2 together with the atoms they are attached to form an optionally substituted ring D, which is selected from 5-6 membered heterocyclic groups and 5-6 membered heteroaryl groups;

[0308] Alternatively, R3 and R6, together with the atoms they are attached to, can form an optionally substituted ring E, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic groups, C 6-10 aryl and 5-8-membered heteroaryl; wherein the ring E is optionally surrounded by one or more R 3a Replaced by, R 3a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 quinone heteroaryl groups;

[0309] or,

[0310] R a or R b R5 and the atoms it is attached to form an optionally substituted ring F, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring F is optionally surrounded by one or more R 4a Replaced by, R 4a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 aryl, 5-8 membered heteroaryl; or R attached to the same atom 4a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 cycloalkyl or 3-8 membered heterocyclic groups;

[0311] or,

[0312] R c or R d R5 and the atoms it is attached to form an optionally substituted ring G, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring G is optionally surrounded by one or more R 5a Replaced by, R 5a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-8 membered heteroaryl; or R attached to the same atom 5a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 cycloalkyl or 3-8 membered heterocyclic groups;

[0313] Alternatively, R8 and R5, together with the atoms they are attached to, can form an optionally substituted ring H, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the cyclic H is optionally surrounded by one or more R 6a Replaced by, R 6a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-8 membered heteroaryl; or R attached to the same atom 6a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 cycloalkyl or 3-8 membered heterocyclic groups;

[0314] or,

[0315] R c or R d R3 and the atoms it is attached to form an optionally substituted ring K, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring K is optionally surrounded by one or more R ka Replaced by, R ka Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 aryl and 5-8 membered heteroaryl; or R attached to two adjacent carbon atoms ka The atoms bonded to it together form optionally substituted 5-8 membered heteroaryl groups;

[0316] or,

[0317] R3 and R8, together with the atoms they are attached to, form an optionally substituted ring M, which is selected from C. s-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein ring M is optionally surrounded by one or more R 8a Replaced by, R 8a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or R attached to two adjacent carbon atoms 8a The atoms attached to it together form optionally substituted 5-8 membered heteroaryl groups.

[0318] This application provides a compound of formula (IA) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0319] in,

[0320] M1 is selected from N, O, NR1, and CR1; R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0321] M2 is selected from N and CR2; R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0322] M3 is selected from N and CR3; R3 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0323] R4 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, =O, C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1- 6-hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8-membered heteroaryl groups may optionally be further converted by deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0324] R5 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0325] L is selected from -NR6- and -CR6R6-, where R6 is independently selected from hydrogen and C. 1-6 alkyl;

[0326] L1 is selected from NR a and CR b , where R a Selected from hydrogen, C 1-6 Alkyl, R b Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy and C1-6 Halogenated alkyl groups;

[0327] L2 is the key, or, selected from NR c CR d N = CR d CR d =CR d and CR c R d -CR c R d , where R c Selected from hydrogen, C 1-6 Alkyl, R d Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Halogenated alkyl groups;

[0328] Ring A is selected from C 6-10 Aryl, 5-8 membered heteroaryl, 5-12 membered fused-ring group and 5-12 membered heterocyclic group;

[0329] Ring B does not exist, or it is selected from C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-8 membered heteroaryl, 5-12 membered fused-ring group and 5-12 membered heterocyclic group;

[0330] R7 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, sulfur pentafluoride, and -S(=O)2R. 7a -S(=O)2NR 7a R 7b R 7a S(=O)2NR 7b -、-N=S(=O)R 7a R 7b R 7a N = S(=O)(R) 7b )-、-C(=O)NR 7a R 7b -P(=O)R 7a R 7b -P(=O)R 7a NR 7a R 7b C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1- 6-Hydroalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 The alkyl group is substituted with one or more substituents in the cycloalkyl and 3-8 membered heterocycloalkyl groups; wherein R 7a R 7b Each is independently selected from hydrogen and C 1-6 alkyl;

[0331] R8 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, sulfur pentafluoride, and -S(=O)2R. 7a -S(=O)2NR 7a R 7b R 7a S(=O)2NR 7b -、-N=S(=O)R 7a R 7b R 7a N = S(=O)(R) 7b )-、-C(=O)NR 7a R 7b -C 1-4 Alkyl C(=O)NR 7a R 7b -P(=O)R 7a R 7b -P(=O)R 7a NR 7a R 7b C1-6 Alkyl, C 2-6 alkenyl, C 2- 6-acetylinyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 The alkyl group is substituted with one or more substituents in the cycloalkyl and 3-8 membered heterocycloalkyl groups; wherein R 7a R 7b Each is independently selected from hydrogen and C 1-6 alkyl;

[0332] or,

[0333] Two R8 atoms attached to the same carbon atom can cyclize into C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic group; or R8 attached to two adjacent carbon atoms co-cyclizes with the attached atoms to form C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups;

[0334] or,

[0335] R1 and R4, together with the atoms they are attached to, form a ring C, which is selected from C. 4-8 Cycloalkyl, 4-8 membered heterocyclic, 5-8 membered heteroaryl and C 6-10 Aryl; ring C can be optionally divided by p R 1a Replaced; R 1a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or two R atoms attached to the same atom 1a Cycloning to C 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups; or two R groups attached to adjacent atoms 1a The atoms it is connected to together form C 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups;

[0336] m, n, and p are each independently selected from 0, 1, 2, 3, and 4;

[0337] or,

[0338] R1 and R2 together with the atoms they are attached to form an optionally substituted ring D, which is selected from 5-6 membered heterocyclic groups and 5-6 membered heteroaryl groups;

[0339] or,

[0340] R3 and R6, together with the atoms they are attached to, form an optionally substituted ring E, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic groups, C 6-10 aryl and 5-8-membered heteroaryl; wherein the ring E is optionally surrounded by one or more R 3a Replaced by, R 3a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-8 quinone heteroaryl groups;

[0341] or,

[0342] R a or R b R5 and the atoms it is attached to form an optionally substituted ring F, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring F is optionally surrounded by one or more R 4a Replaced by, R 4a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-8 membered heteroaryl; or R attached to the same atom 4a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 cycloalkyl or 3-8 membered heterocyclic groups;

[0343] or,

[0344] R c or R d R5 and the atoms it is attached to form an optionally substituted ring G, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring G is optionally surrounded by one or more R 5a Replaced by, R 5a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-8 quinone heteroaryl groups;

[0345] Alternatively, R8 and R5, together with the atoms they are attached to, can form an optionally substituted ring H, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the cyclic H is optionally surrounded by one or more R 6a Replaced by, R 6a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 Aryl and 5-8 membered heteroaryl; or R attached to the same atom 6a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 cycloalkyl or 3-8 membered heterocyclic groups;

[0346] or,

[0347] R c or R d R3 and the atoms it is attached to form an optionally substituted ring K, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring K is optionally surrounded by one or more R ka Replaced by, R ka Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C3- 8-cyclic alkenyl, 3-8 membered heterocyclic group, C 6-10 aryl and 5-8 membered heteroaryl; or R attached to two adjacent carbon atoms ka The atoms bonded to it together form optionally substituted 5-8 membered heteroaryl groups;

[0348] or,

[0349] R3 and R8, together with the atoms they are attached to, form an optionally substituted ring M, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein ring M is optionally surrounded by one or more R 8a Replaced by, R 8a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or R attached to two adjacent carbon atoms 8a The atoms attached to it together form optionally substituted 5-8 membered heteroaryl groups.

[0350] This application provides a compound of formula (I) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0351] in,

[0352] M1 is selected from N, O, NR1, and CR1; R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0353] M2 is selected from N and CR2; R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0354] M3 is selected from N and CR3; R3 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0355] R4 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, =O, C. 1-6 Alkyl, C 2-6 alkenyl, C2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1- 6-hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0356] R5 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups;

[0357] L is selected from -NR6- and -CR6R6-, where R6 is independently selected from hydrogen and C. 1-6 alkyl;

[0358] Ring A is selected from C 6-10 Aryl, 5-8 membered heteroaryl, 5-12 membered fused-ring group and 5-12 membered heterocyclic group;

[0359] Ring B is selected from C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-8 membered heteroaryl, 5-12 membered fused-ring group and 5-12 membered heterocyclic group;

[0360] R7 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, sulfur pentafluoride, and -S(=O)2R. 7a -S(=O)2NR 7a R 7b R 7a S(=O)2NR 7b -、-N=S(=O)R 7a R 7b R 7a N = S(=O)(R) 7b )-、-C(=O)NR 7a R 7b -P(=O)R 7a R 7b -P(=O)R 7a NR 7a R 7b -、C 1-6 Alkyl, C2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1- 6-alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 The alkyl group is substituted with one or more substituents in the cycloalkyl and 3-8 membered heterocycloalkyl groups; wherein R 7a R 7b Each is independently selected from hydrogen and C 1-6 alkyl;

[0361] R8 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, sulfur pentafluoride, and -S(=O)2R. 7a -S(=O)2NR 7a R 7b R 7a S(=O)2NR 7b -、-N=S(=O)R 7a R 7b R 7a N = S(=O)(R) 7b )-、-C(=O)NR 7a R 7b -C 1-4Alkyl C(=O)NR 7a R 7b -P(=O)R 7a R 7b -P(=O)R 7a NR 7a R 7b -、C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1- 6-Hydroalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 The alkyl group is substituted with one or more substituents in the cycloalkyl and 3-8 membered heterocycloalkyl groups; wherein R 7a R 7b Each is independently selected from hydrogen and C 1-6 alkyl;

[0362] Alternatively, two R8 atoms attached to the same carbon atom can cyclize into C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic group; or R8 attached to two adjacent carbon atoms co-cyclizes with the attached atoms to form C. 3-8 cycloalkyl, C3-8 Cycloalkenyl or 3-8 membered heterocyclic groups;

[0363] Alternatively, R1 and R4, together with the atoms they are attached to, form a ring C, which is selected from C. 4-8 Cycloalkyl, 4-8 membered heterocyclic, 5-8 membered heteroaryl and C 6-10 Aryl; ring C can be optionally divided by p R 1a Replaced; R 1a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or two R atoms attached to the same atom 1a Cycloning to C 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups; or two R groups attached to adjacent atoms 1a The atoms it is connected to together form C 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups;

[0364] m, n, and p are each independently selected from 0, 1, 2, 3, and 4;

[0365] Alternatively, R1 and R2 together with the atoms they are attached to form an optionally substituted ring D, which is selected from 5-6 membered heterocyclic groups and 5-6 membered heteroaryl groups;

[0366] Alternatively, R3 and R6, together with the atoms they are attached to, can form an optionally substituted ring E, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic groups, C 6-10 aryl and 5-8-membered heteroaryl; wherein the ring E is optionally surrounded by one or more R 3a Replaced by, R 3a Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 heteroaryl compounds.

[0367] In some embodiments of this application, certain groups in the compound represented by formula (IB), its stereoisomers, or pharmaceutically acceptable salts thereof may be defined as follows, and other groups may be defined as described in any embodiment of this application (hereinafter referred to as "in some embodiments of this application").

[0368] In some embodiments of this application, R1 is selected from hydrogen, halogen, C 1-4 Alkyl and C 1-4 Halogenated alkyl groups.

[0369] In some embodiments of this application, R1 is selected from hydrogen, fluorine, bromine, chlorine, methyl, and trifluoromethyl.

[0370] In some embodiments of this application, R1 is selected from hydrogen, fluorine, methyl, and trifluoromethyl.

[0371] In some embodiments of this application, R1 is selected from bromine and chlorine.

[0372] In some embodiments of this application, R1 is hydrogen.

[0373] In some embodiments of this application, M1 is selected from CH, NH, O, N, CF, CCF3, CCH3, CCl and CBr.

[0374] In some embodiments of this application, M1 is selected from CH, NH, O, N, CF, CCF3 and CCH3.

[0375] In some embodiments of this application, M1 is selected from CCl and CB. r .

[0376] In some embodiments of this application, R1 is hydrogen and M1 is CH.

[0377] In some embodiments of this application, R3 is selected from...

[0378] In some embodiments of this application, R4 is selected from C. 3-8 cycloalkyl and C 1-6 Alkyl group. In some embodiments of this application, R4 is selected from cyclopropyl or methyl.

[0379] In some embodiments of this application, R4 is selected from =O, C 3-8 cycloalkyl, C1-6 Alkyl and C 1-6 Halogenated alkoxy groups.

[0380] In some embodiments of this application, R4 is selected from =O, cyclopropyl, methyl, ethyl, isopropyl, -OCHF2, and -OCF3.

[0381] In some embodiments of this application, R4 is = 0.

[0382] In some embodiments of this application, R4 is C 3-8 Cycloalkyl.

[0383] In some embodiments of this application, R4 is cyclopropyl.

[0384] In some embodiments of this application, R4 is C 1-6 alkyl.

[0385] In some embodiments of this application, R4 is C 1-6 Halogenated alkoxy groups.

[0386] In some embodiments of this application, R4 is methyl.

[0387] In some embodiments of this application, R4 is selected from ethyl, isopropyl, -OCHF2, and -OCF3.

[0388] In some embodiments of this application, R5 is C 3-8 Cycloalkyl.

[0389] In some embodiments of this application, R5 is cyclopropyl.

[0390] In some embodiments of this application, R6 is hydrogen, methyl, methoxy, -CD3,

[0391] In some embodiments of this application, R6 is methyl.

[0392] In some embodiments of this application, R6 is selected from In some embodiments of this application, L is selected from -N(CH3)-, -NH-, -CH(OCH3)-, -N(OCH3)-, -C(=O)-, -N(CD3)-,

[0393] In some embodiments of this application, L is -N(CH3)- or -N(CD3)-.

[0394] In some embodiments of this application, L is -N(CH3)-.

[0395] In some embodiments of this application, L is -NH-.

[0396] In some embodiments of this application, L is -N(CD3)-.

[0397] In some embodiments of this application, L is selected from

[0398] In some embodiments of this application, L is

[0399] In some embodiments of this application, L is

[0400] In some embodiments of this application, L1 is -NH-, -CH(NH2)-, -CH(OCH3)-, -N(OCH3)- or -C(=O)-.

[0401] In some embodiments of this application, L1 is selected from -NH- and -CH(NH2)-.

[0402] In some embodiments of this application, L1 is -NH-.

[0403] In some embodiments of this application, L1 is selected from -CH(OCH3)-, -N(OCH3)- and -C(=O)-.

[0404] In some embodiments of this application, L2 is a bond, O, S, NH, or -NHC(=O)-.

[0405] In some embodiments of this application, L2 is the key.

[0406] In some embodiments of this application, L2 is 0.

[0407] In some embodiments of this application, L2 is S.

[0408] In some embodiments of this application, L2 is -NHC(=O)-.

[0409] In some embodiments of this application, R7 is selected from hydrogen, halogens, sulfur pentafluoride, and -S(=O)2R. 7a R 7a S(=O)2NR 7b - 5-8 membered heterocyclic group, -S(=O)2N 7a R 7b R 7a N = S(=O)(R) 7b )-、-P(=O)R 7a R 7band -C(=O)NR 7a R 7b The R mentioned therein 7a R 7b Each is independently selected from hydrogen, C 1-6 Alkyl, C 3-8 cycloalkyl and C 1- 6-alkoxy group.

[0410] In some embodiments of this application, R7 is selected from H, F, SF5, -S(=O)2CH3, CH3S(=O)2NH-,

[0411] In some embodiments of this application, R7 is selected from hydrogen, halogens, sulfur pentafluoride, and -S(=O)2R. 7a R 7a S(=O)2NR 7b - and 5-8 membered heterocyclic groups, wherein the R 7a R 7b As defined above.

[0412] In some embodiments of this application, R7 is -S(=O)2N 7a R 7b The R mentioned therein 7a R 7b Each is independently selected from hydrogen, C 1-6 Alkyl, C 3-8 cycloalkyl and C 1-6 Alkyl group.

[0413] In some embodiments of this application, R7 is R 7a N = S(=O)(R) 7b )-, wherein R 7a R 7b Each is independently selected from hydrogen, C 1-6 Alkyl, C 3-8 cycloalkyl and C 1-6 Alkyl group.

[0414] In some embodiments of this application, R7 is selected from -P(=O)R 7a R 7b and -C(=O)NR 7a R 7b The R mentioned therein 7a R 7b Each is independently selected from hydrogen, C 1-6 Alkyl, C 3-8 cycloalkyl and C 1-6 Alkyl group.

[0415] In some embodiments of this application, R7 is selected from H, F, SF5, -S(=O)2CH3, CH3S(=O)2NH- and

[0416] In some embodiments of this application, R7 is

[0417] In some embodiments of this application, R7 is

[0418] In some embodiments of this application, R7 is selected from

[0419] In some embodiments of this application, R7 is selected from

[0420] In some embodiments of this application, ring A is selected from phenyl, benzo5-6 membered heterocyclic groups, and benzoC. 5-6 Cycloalkyl.

[0421] In some embodiments of this application, ring A is selected from...

[0422] In some embodiments of this application, structural units Selected from

[0423] In some embodiments of this application, structural units Selected from

[0424] In some embodiments of this application, structural units for

[0425] In some embodiments of this application, structural units for

[0426] In some embodiments of this application, structural units Selected from

[0427] In some embodiments of this application, structural units Selected from

[0428] In some embodiments of this application, structural units for

[0429] In some embodiments of this application, R8 is selected from hydrogen, deuterium, and C. 1-4 Alkyl, -C(=O)NR 7a R 7b -C 1-4 Alkyl C(=O)NR 7a R 7b -C(=O)R 7a -C(=O)OR 7a C 3-8 Cycloalkyl, 3-8 membered heterocyclic, 5-8 membered heteroaryl, C 1-4 Halogenated alkyl, halogen, hydroxyl, cyano, C 1-6 Hydroxyalkyl and C 1-6 Alkoxy, of which, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, 5-8 membered heteroaryl, C 1-4 The alkyl group is optionally substituted, and the substituent is selected from deuterium, halogen, amino, hydroxyl, cyano, C. 1- 6-alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 One or more of cycloalkyl, 3-8 membered heterocyclic alkyl; or two R8 atoms attached to the same carbon atom can cyclize to C. 3-8 cycloalkyl; wherein R 7a R 7b Each is independently selected from hydrogen, C 1-4 Haloalkyl, C 1-6 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocycloalkyl, wherein the C 3-8 Cycloalkyl groups and 3-8-membered heterocycloalkyl groups may optionally be substituted with one or more groups selected from the following groups: deuterium, halogen, amino, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Hydroxyalkyl and C 1-4 Alkyl group.

[0430] In some embodiments of this application, R8 is selected from hydrogen, C 1-4 Alkyl, -C(=O)NR 7a R 7b -C 1-4 Alkyl C(=O)NR 7a R 7b -C(=O)R 7a-C(=O)OR 7a C 3-8 Cycloalkyl, 3-8 membered heterocyclic, 5-8 membered heteroaryl, C 1-4 Halogenated alkyl, halogen, hydroxyl, cyano, C 1-6 Hydroxyalkyl and C 1-6 Alkoxy, of which, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, 5-8 membered heteroaryl and C 1-4 The alkyl group is optionally substituted, and the substituent is selected from deuterium, halogen, amino, hydroxyl, cyano, C. 1-6 Alkyl, C 2- 6-alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 One or more of cycloalkyl and 3-8 membered heterocyclic alkyl groups; or two R8s attached to the same carbon atom can cyclize to C. 3-8 cycloalkyl; wherein R 7a R 7b Each is independently selected from hydrogen, C 1-4 Haloalkyl, C 1-6 Alkyl, C 3-8 Cycloalkyl and 3-8 membered heterocycloalkyl, wherein the C 3-8 Cycloalkyl and 3-8 membered heterocycloalkyl groups may optionally be substituted with one or more groups selected from the following groups: deuterium, halogen, amino, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Hydroxyalkyl, C 1-4 Alkyl group.

[0431] In some embodiments of this application, R8 is selected from hydrogen, C 1-4 Alkyl, -C(=O)NR 7a R 7b -C 1-4 Alkyl C(=O)NR 7a R 7b C 3-8 cycloalkyl, 5-8 membered heteroaryl, C 1-4 Halogenated alkyl, halogen, hydroxyl, cyano, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, of which, C 3-8 cycloalkyl, 5-8 membered heteroaryl, C 1-4 The alkyl group is optionally substituted, and the substituent is selected from deuterium, halogen, amino, hydroxyl, cyano, C. 1-6 Alkyl, C 2-6alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1- 6-hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 One or more of cycloalkyl, 3-8 membered heterocyclic alkyl; or two R8 atoms attached to the same carbon atom can cyclize to C. 3-8 cycloalkyl; wherein R 7a R 7b Each is independently selected from hydrogen or C 1-6 alkyl.

[0432] In some embodiments of this application, R8 is selected from hydrogen, C 1-4 Alkyl, -C(=O)NR 7a R 7b -C 1-4 Alkyl C(=O)NR 7a R 7b Alternatively, two R8 atoms attached to the same carbon atom can cyclize into C. 3-8 cycloalkyl, wherein C 3-8 The cycloalkyl group is optionally substituted, and the substituent types are as defined above; wherein R 7a R 7b As defined in any technical solution of this application.

[0433] In some embodiments of this application, R8 is selected from C. 3-8 Cycloalkyl, 5-8-membered heteroaryl, wherein the 5-8-membered heteroaryl are optionally substituted, and the substituent types are as defined above.

[0434] In some embodiments of this application, R8 is selected from hydrogen, C 1-4 Alkyl, -C(=O)NR 7a R 7b -C 1-4 Alkyl C(=O)NR 7a R 7b C 3-8 cycloalkyl, 5-8 membered heteroaryl, C 1-4 Halogenated alkyl groups, halogens, wherein C 3-8 cycloalkyl, 5-8 membered heteroaryl, C 1-4 The alkyl group is optionally substituted, and the substituent types are as defined above.

[0435] In some embodiments of this application, R8 is selected from hydrogen, CH3, Cyclopropyl, CF3, F, Br, Cl, I, ethyl, -CH2CF3, isopropyl, tert-butyl, -CH2CN -CN, -OH, - Deuterium, CHF2, Alternatively, two R8 atoms attached to the same carbon atom can cyclize into a cyclopropyl group.

[0436] In some embodiments of this application, R8 is C 1-4 Halogenated alkyl groups.

[0437] In some embodiments of this application, R8 is a halogen.

[0438] In some embodiments of this application, R8 is deuterium.

[0439] In some embodiments of this application, R8 is selected from... And cyclopropyl.

[0440] In some embodiments of this application, R8 is selected from hydrogen, CH3, Alternatively, two R8 atoms attached to the same carbon atom can cyclize into a cyclopropyl group.

[0441] In some embodiments of this application, R8 is CF3.

[0442] In some embodiments of this application, R8 is selected from F, Br, Cl, I, ethyl and -CH2CF3.

[0443] In some embodiments of this application, R8 is isopropyl.

[0444] In some embodiments of this application, R8 is selected from tert-butyl, -CH2CN, and

[0445] In some embodiments of this application, R8 is selected from... -CN, -OH, -OCH3 and

[0446] In some embodiments of this application, R8 is

[0447] In some embodiments of this application, R8 is

[0448] In some embodiments of this application, R8 is selected from...

[0449] In some embodiments of this application, R8 is selected from...

[0450] In some embodiments of this application, R8 is selected from deuterium, CHF2,

[0451] In some embodiments of this application, R8 is selected from...

[0452] In some embodiments of this application, n is selected from 0, 1, 2, and 3.

[0453] In some embodiments of this application, ring B does not exist, n is 1, and L2 and R8 are directly connected.

[0454] In some embodiments of this application, ring B is selected from...

[0455] In some embodiments of this application, ring B is selected from 5-6-membered heteroaryl and 5-6-membered heteroaryl with 5-8-membered heterocyclic group.

[0456] In some embodiments of this application, ring B is a 5-6 membered heteroaryl group containing 1-3 nitrogen atoms.

[0457] In some embodiments of this application, ring B is selected from C. 3-6 Cycloalkyl and 3-6 membered heterocyclic groups.

[0458] In some embodiments of this application, ring B is phenyl.

[0459] In some embodiments of this application, ring B is selected from 5-6-membered heteroaryl and 5-8-membered heterocyclic groups, wherein ring B contains 1-3 heteroatoms selected from N and O.

[0460] In some embodiments of this application, ring B is selected from...

[0461] In some embodiments of this application, ring B is selected from... In some embodiments of this application, ring B is selected from...

[0462] In some embodiments of this application, ring B is selected from...

[0463] In some embodiments of this application, ring B is selected from...

[0464] In some embodiments of this application, ring B is selected from...

[0465] In some embodiments of this application, ring B is selected from...

[0466] In some embodiments of this application, ring B is selected from...

[0467] In some embodiments of this application, ring B is selected from...

[0468] In some embodiments of this application, ring B is selected from...

[0469] In some embodiments of this application, ring B is selected from...

[0470] In some embodiments of this application, ring B is selected from...

[0471] In some embodiments of this application, ring B is selected from...

[0472] In some embodiments of this application, ring B is selected from...

[0473] In some embodiments of this application, ring B is selected from...

[0474] In some embodiments of this application, ring B is selected from...

[0475] In some embodiments of this application, ring B is selected from...

[0476] In some embodiments of this application, ring B is selected from...

[0477] In some embodiments of this application, ring B is selected from...

[0478] In some embodiments of this application, structural units Selected from

[0479] In some embodiments of this application, the unit Selected from

[0480] In some embodiments of this application, the unit Selected from

[0481] In some embodiments of this application, the unit Selected from

[0482] In some embodiments of this application, the unit Selected from

[0483] In some embodiments of this application, the unit Selected from

[0484] In some embodiments of this application, the unit Selected from

[0485] In some embodiments of this application, the unit Selected from

[0486] In some embodiments of this application, the unit Selected from

[0487] In some embodiments of this application, the unit Selected from

[0488] In some embodiments of this application, the unit Selected from

[0489] In some embodiments of this application, the unit Selected from

[0490] In some embodiments of this application, the unit Selected from

[0491] In some embodiments of this application, the unit Selected from

[0492] In some embodiments of this application, the unit Selected from

[0493] In some embodiments of this application, the unit Selected from

[0494] In some embodiments of this application, the unit Selected from

[0495] In some embodiments of this application, the unit Selected from

[0496] In some embodiments of this application, the unit Selected from

[0497] In some embodiments of this application, the unit Selected from

[0498] In some embodiments of this application, ring C is selected from C 48 cycloalkyl and C 6-10 Aryl, cyclic C is optionally replaced by R 1a Substitution, preferably, is preferred, with ring C being unsubstituted.

[0499] In some embodiments of this application, the ring C is selected from cyclohexyl and phenyl, and the ring C is optionally converted by R. 1a The preferred substitution is that ring C is unsubstituted.

[0500] In some embodiments of this application, ring C is C 4-8 Cycloalkyl.

[0501] In some embodiments of this application, cycloC is cyclohexyl.

[0502] In some embodiments of this application, ring C is C 6-10 Aryl.

[0503] In some embodiments of this application, the ring C is phenyl.

[0504] In some embodiments of this application, R 1a It is a methyl group, or two R atoms attached to the same atom. 1a It cyclizes to a cyclopropyl group.

[0505] In some embodiments of this application, R 1a It is methyl.

[0506] In some embodiments of this application, two R atoms connected to the same atom 1a It cyclizes to a cyclopropyl group.

[0507] In some embodiments of this application, when R1 and R4 are cyclic with the atoms they are connected to, the structural unit... Selected from

[0508] In some embodiments of this application, when R1 and R4 are cyclic with the atoms they are connected to, the structural unit... Selected from

[0509] In some embodiments of this application, when R1 and R4 are cyclic with the atoms they are connected to, the structural unit... for

[0510] In some embodiments of this application, when R1 and R4 are decycliced ​​with the atoms they are connected to, the structural unit... Selected from

[0511] Preferred structural unit for

[0512] In some embodiments of this application, when R1 and R4 are decycliced ​​with the atoms they are connected to, the structural unit... Selected from

[0513] In some embodiments of this application, when R1 and R4 are decycliced ​​with the atoms they are connected to, the structural unit... Selected from

[0514] In some embodiments of this application, when R1 and R4 are decycliced ​​with the atoms they are connected to, the structural unit... Selected from

[0515] In some embodiments of this application, when R1 and R4 are decycliced ​​with the atoms they are connected to, the structural unit... Selected from

[0516] In some embodiments of this application, when R1 and R4 are decycliced ​​with the atoms they are connected to, the structural unit... for

[0517] In some embodiments of this application, ring D is a 5-6 member heterocyclic group.

[0518] In some embodiments of this application, ring D is a morpholine ring.

[0519] In some embodiments of this application, ring D is

[0520] In some embodiments of this application, ring E is selected from phenyl, 5-6 membered heterocyclic and 5-6 membered heteroaryl.

[0521] In some embodiments of this application, ring E is selected from

[0522] In some embodiments of this application, structural units Selected from

[0523] In some embodiments of this application, structural units Selected from

[0524] In some embodiments of this application, structural units Selected from

[0525] In some embodiments of this application, structural units Selected from

[0526] In some embodiments of this application, structural units for

[0527] In some embodiments of this application, structural units Selected from

[0528] In some embodiments of this application, structural units for

[0529] In some embodiments of this application, structural units Selected from

[0530] In some embodiments of this application, ring F is a 5-8 membered heterocyclic group.

[0531] In some embodiments of this application, ring F is selected from

[0532] In some embodiments of this application, ring F is selected from

[0533] In some embodiments of this application, ring F and The formed ring structure is selected from

[0534] In some embodiments of this application, ring F and The formed ring structure is selected from

[0535] In some embodiments of this application, two R atoms bonded to the same carbon atom 4a Together with the attached carbon atom, it forms a cyclopropyl group.

[0536] In some embodiments of this application, R 5a Selected from C 3-6 cycloalkyl, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 2-4 alkynyl group, C 1-4 Haloalkoxy, -NR 5aa R 5ab Hydrogen and deuterium, or two R atoms bonded to the same carbon atom. 5a Together with the connected carbon atoms, they form C 3-6 cycloalkyl, wherein R 5aa and R 5ab Each is independently selected from hydrogen and C. 1-4 alkyl.

[0537] In some embodiments of this application, R 5a Selected from C 3-6 cycloalkyl and C 1-3 alkyl.

[0538] In some embodiments of this application, R 5a C 1-3 alkyl.

[0539] In some embodiments of this application, R 5aC 3-8 Cycloalkyl.

[0540] In some embodiments of this application, R 5a Selected from C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0541] In some embodiments of this application, R 5a C 1-6 Hydroxyalkyl.

[0542] In some embodiments of this application, R 5a It is cyclopropyl.

[0543] In some embodiments of this application, R 5a Selected from methyl, ethyl and 1,1,1-trifluoroethyl.

[0544] In some embodiments of this application, R 5a It is an ethyl group.

[0545] In some embodiments of this application, two R atoms bonded to the same carbon atom 5a Together with the attached carbon atom, it forms a cyclopropyl group.

[0546] In some embodiments of this application, R 5a C 1-4 Halogenated alkoxy groups.

[0547] In some embodiments of this application, R 5a Selected from cyclopropyl, methyl, ethyl, 1,1,1-trifluoroethyl, -OCH3, -CH2CF3, -CH(CH3)2, -C≡CH, -N(CH3)2, -CH2OH、 -OCHF2, CF3, hydrogen, deuterium, -OCH2CH3 and -NHCH3, or two Rs attached to the same carbon atom. 5a Together with the attached carbon atom, it forms a cyclopropyl group.

[0548] In some embodiments of this application, R 5a Selected from cyclopropyl, methyl, and ethyl.

[0549] In some embodiments of this application, R 5a It is an ethyl group.

[0550] In some embodiments of this application, R 5a The values ​​are -OCH3, -CH2CF3, -CH(CH3)2, -C≡CH and -N(CH3)2.

[0551] In some embodiments of this application, R5a for

[0552] In some embodiments of this application, R 5a Selected from -CH2OH.

[0553] In some embodiments of this application, R 5a Selected from C 3-6 cycloalkyl, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 2-4 acetylinyl and -NR 5aa R 5ab Or two Rs connected to the same carbon atom 5a Together with the connected carbon atoms, they form C 3-6 cycloalkyl, wherein R 5aa and R 5ab Each is independently selected from hydrogen and C. 1-4 alkyl.

[0554] In some embodiments of this application, R 5a C 1-4 Halogenated alkoxy groups.

[0555] In some embodiments of this application, R 5a Selected from cyclopropyl, methyl, ethyl, 1,1,1-trifluoroethyl, -OCH3, -CH2CF3, -CH(CH3)2, -C≡CH, -N(CH3)2, and -CH2OH.

[0556] In some embodiments of this application, R 5a Selected from

[0557] In some embodiments of this application, R 5a It is -OCHF2.

[0558] In some embodiments of this application, R 5a Selected from CF3, hydrogen, deuterium, and -OCH2CH3, or two R atoms attached to the same carbon atom. 5a Together with the attached carbon atom, it forms a cyclopropyl group.

[0559] In some embodiments of this application, R 5a It is -NHCH3.

[0560] In some embodiments of this application, ring G is selected from 5-8 membered heteroaryl, 5-8 membered heterocyclic and C. 5-8 Cycloalkenyl, cycloG optionally replaced by R5a replace.

[0561] In one embodiment of this application, ring G is selected from 5-8 membered heteroaryl, 5-8 membered heterocyclic and C. 5-8 Cycloalkenyl.

[0562] In some embodiments of this application, ring G is a 5-8 membered heteroaryl group.

[0563] In some embodiments of this application, ring G is selected from Ring G can be arbitrarily selected by R 5a replace.

[0564] In some embodiments of this application, ring G is selected from

[0565] In some embodiments of this application, ring G is selected from

[0566] In some embodiments of this application, ring G is selected from

[0567] In some embodiments of this application, ring G is

[0568] In some embodiments of this application, ring G is selected from

[0569] In some embodiments of this application, ring G and The formed ring structure is selected from: Ring G can be arbitrarily selected by R 5a replace.

[0570] In some embodiments of this application, ring G and The formed ring structure is selected from:

[0571] In some embodiments of this application, ring G and The formed ring structure is Ring G can be arbitrarily selected by R 5a replace.

[0572] In some embodiments of this application, ring G and The formed ring structure is selected from

[0573] In some embodiments of this application, ring G and The formed ring structure is selected from

[0574] In some embodiments of this application, ring G and The formed ring structure is

[0575] In some embodiments of this application, ring G and The resulting structural unit is

[0576] In some embodiments of this application, ring G and The formed ring structure is

[0577] In some embodiments of this application, ring G and The formed ring structure is

[0578] In some embodiments of this application, ring G and The structural units formed are selected from Where R 5a As defined in any technical solution of this application.

[0579] In some embodiments of this application, ring G and The resulting structural unit is Where R 5a As defined in any of the technical solutions in this application.

[0580] In some embodiments of this application, ring G and The resulting structural unit is Where R 5a As defined in any technical solution of this application.

[0581] In some embodiments of this application, ring G and The structural units formed are selected from Where R 5a As defined in any technical solution of this application.

[0582] In some embodiments of this application, ring G and The structural units formed are selected from

[0583] In some embodiments of this application, ring G and The structural units formed are selected from R 5a As defined in any technical solution of this application.

[0584] In some embodiments of this application, ring G and The structural units formed are selected from Where R 5a1 Each element is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-8 quinone heteroaryl, -NR 5a2 R 5a3 ; or R connected to the same atom 5a1 It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 Cycloalkyl, 3-8 membered heterocyclic groups; of which, R5 a2 and R 5a3 Each is independently selected from hydrogen and C. 1-4 Alkyl; R 5a As defined in any technical solution of this application.

[0585] In some embodiments of this application, ring G and The structural units formed are selected from Where R 5a As defined in any technical solution of this application.

[0586] In some embodiments of this application, ring G and The structural units formed are selected from Where R 5a As defined in any technical solution of this application.

[0587] In some embodiments of this application, ring G and The structural units formed are selected from Where R 5a As defined in any technical solution of this application.

[0588] In some embodiments of this application, ring G and The structural units formed are selected from Where R 5aAs defined in any technical solution of this application.

[0589] In some embodiments of this application, ring G and The structural units formed are selected from

[0590] In some embodiments of this application, ring G and The resulting structural unit is

[0591] In some embodiments of this application, ring G and The resulting structural unit is

[0592] In some embodiments of this application, ring G and The resulting structural unit is

[0593] In some embodiments of this application, ring G and The resulting structural unit is

[0594] In some embodiments of this application, ring G and The resulting structural unit is

[0595] In some embodiments of this application, ring G and The resulting structural unit is

[0596] In some embodiments of this application, ring G and The resulting structural unit is

[0597] In some embodiments of this application, ring G and The resulting structural unit is

[0598] In some embodiments of this application, ring H is selected from 5-8 membered heterocyclic groups and C. 5-8 Cycloalkenyl, cyclic H optionally replaced by R 6a Substitution, preferably, with ring H being unsubstituted.

[0599] In some embodiments of this application, ring H is a 5-8 membered heterocyclic group.

[0600] In some embodiments of this application, ring H is selected from Ring H is arbitrarily assigned to R6a Substitution, preferably, with ring H being unsubstituted.

[0601] In some embodiments of this application, ring H is selected from

[0602] In some embodiments of this application, ring H is

[0603] In some embodiments of this application, ring B, ring H and The formed ring structure is selected from Ring H is optionally substituted, preferably unsubstituted.

[0604] In some embodiments of this application, ring B, ring H and The formed ring structure is selected from

[0605] In some embodiments of this application, ring B, ring H and The formed ring structure is selected from

[0606] In some embodiments of this application, ring B, ring H and The formed ring structure is

[0607] In some embodiments of this application, ring B, ring H and The formed ring structure is selected from

[0608] In some embodiments of this application, R 6a Selected from C 1-6 Alkyl and C 3-6 cycloalkyl, or R attached to the same carbon atom 6a The carbon atoms bonded to it together form C 3-6 Cycloalkyl.

[0609] In some embodiments of this application, R 6a Selected from methyl, ethyl, isopropyl, and cyclopropyl, or R groups attached to the same carbon atom. 6a The carbon atoms connected to it together form a cyclopropyl group.

[0610] In some embodiments of this application, R 6a Selected from cyclopropyl and isopropyl, or R groups attached to the same carbon atom6a The carbon atoms connected to it together form a cyclopropyl group.

[0611] In some embodiments of this application, R 6a Selected from methyl and ethyl.

[0612] In some embodiments of this application, R 6a It is cyclopropyl.

[0613] In some embodiments of this application, ring K is selected from

[0614] In some embodiments of this application, ring K and The formed ring structure is selected from

[0615] In some embodiments of this application, R ka Selected from hydrogen and optionally substituted 5-8 membered heteroaryl groups; preferably, R ka Selected from hydrogen and

[0616] In some embodiments of this application, ring M is selected from...

[0617] In some embodiments of this application, ring M and The formed ring structure is selected from

[0618] In some embodiments of this application, ring M, The ring system structure formed with ring B is selected from

[0619] In some embodiments of this application, L3 is selected from -(CH2)3-, -(CH2)4-, -(CH2)2O(CH2)-, -(CH2)O(CH2)2- and -(CH2)2O(CH2)2-.

[0620] In some embodiments of this application, the compound or its stereoisomers, or pharmaceutically acceptable salts, are characterized in that the compound is selected from the following structures:

[0621] Among them, M1, M2, M3, R4, R5, R7, R8, R 1a Rings A, B, C, D, E, L, m, n, and p are as defined in any technical solution of this application, wherein rings A, B, C, and D are optional substitutions.

[0622] In some embodiments of this application, the compound or its stereoisomers, or pharmaceutically acceptable salts, are characterized in that the compound is selected from the following structures:

[0623] Among them, M1, M2, M3, Rx, R5, R7, R8, R 1a Rings A, B, C, D, E, F, G, H, K, M, L, L1, L2, m, n, and p are as defined in any technical solution of this application, wherein rings A, B, C, D, E, F, G, H, K, and M are optional substitutions.

[0624] In some embodiments of this application, rings A, B, C, D, E, F, G, H, K, and M are all optionally substituted, and the definitions of each substituent are as defined in any technical solution of this application.

[0625] In some embodiments of this application, the compound or its stereoisomers, or pharmaceutically acceptable salts, are characterized in that the compound is selected from the following structures:

[0626] Wherein, M1, M2, M3, R4, R5, R7, R8, ring A, ring B, L, L1, L2, L3, m, and n are as defined in any technical solution of this application.

[0627] In some embodiments of this application, the compound or its stereoisomers, or pharmaceutically acceptable salts, are characterized in that the compound is selected from the following structures:

[0628] Wherein, M1, M2, M3, R4, R5, R7, R8, L, L1, L2, L3, m, and n are as defined in any technical solution of this application;

[0629] R8 is a substituent at any site on ring B1 or ring B2;

[0630] Ring B1 is a 5-membered heteroaromatic ring, preferably with N as the heteroatom and 1, 2 or 3 heteroatoms.

[0631] Ring B2 is a 7-membered monocyclic heterocyclic ring.

[0632] In some embodiments of this application, for

[0633] In some embodiments of this application, the compound or its stereoisomers, or pharmaceutically acceptable salts, are characterized in that the compound is selected from the following structures:

[0634] Among them, M1, M2, M3, R4, R 6a R7, R8, ring A, ring B, L, L1, m, n, as defined in any technical solution of this application.

[0635] In some embodiments of this application, the compound or its stereoisomers, or pharmaceutically acceptable salts, are characterized in that the compound is selected from the following structures:

[0636] Among them, R4, R 6a R8, ring B, and n are as defined in any technical solution of this application.

[0637] In some embodiments of this application, the compound or its stereoisomers, or pharmaceutically acceptable salts, are characterized in that the compound is selected from the following structures:

[0638] Among them, R4, R 6a R8, ring B, and n are as defined in any technical solution of this application.

[0639] In some embodiments of this application, the compound or its stereoisomers, or pharmaceutically acceptable salts, are characterized in that the compound is selected from the following structures:

[0640] Among them, R4, R 5a R8, ring B, and n are as defined in any technical solution of this application;

[0641] R 5a1 Each element is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-8 quinone heteroaryl and -NR 5a2 R 5a3 ; or R connected to the same atom 5a1It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 cycloalkyl, 3-8 membered heterocyclic groups; wherein, R 5a2 and R 5a3 Each is independently selected from hydrogen and C. 1-4 alkyl;

[0642] q is selected from 0, 1, 2, 3 or 4.

[0643] In some embodiments of this application, the compound or its stereoisomers, or pharmaceutically acceptable salts, are characterized in that the compound has the following structure:

[0644] in,

[0645] R4 is selected from C 3-8 cycloalkyl and C 1-6 Alkyl; preferably, R4 is selected from cyclopropyl and methyl; more preferably, R4 is selected from methyl;

[0646] R 5a Selected from C 3-6 cycloalkyl and C 1-3 Alkyl; preferably, R 5a Selected from cyclopropyl, methyl, and ethyl; more preferably, R 5a It is ethyl;

[0647] Ring B is a 5-6 membered heteroaryl group containing 1-3 nitrogen atoms; preferably, ring B is...

[0648] R8 is selected from hydrogen, deuterium, and C. 1-4 Alkyl, -C(=O)NR 7a R 7b -C 1-4 Alkyl C(=O)NR 7a R 7b -C(=O)R 7a -C(=O)OR 7a C 3-8 Cycloalkyl, 3-8 membered heterocyclic, 5-8 membered heteroaryl, C 14 Halogenated alkyl, halogen, hydroxyl, cyano, C 1-6 Hydroxyalkyl and C 1-6 Alkoxy, of which, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, 5-8 membered heteroaryl and C 1-4 The alkyl group is optionally substituted, and the substituent is selected from deuterium, halogen, amino, hydroxyl, cyano, C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1- 6-Deuterated Alkyl, C 1-6Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 One or more of cycloalkyl and 3-8 membered heterocyclic alkyl groups; or two R8s attached to the same carbon atom can cyclize to C. 3-8 cycloalkyl; wherein R 7a R 7b Each is independently selected from hydrogen, C 1-4 Haloalkyl, C 1-6 Alkyl, C 3-8 Cycloalkyl and 3-8 membered heterocycloalkyl, wherein the C 3-8 Cycloalkyl groups and 3-8 membered heterocycloalkyl groups may optionally be substituted with one or more groups selected from the following: deuterium, halogen, amino, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Hydroxyalkyl and C 1-4 Alkyl group; preferably, R8 is selected from hydrogen, CH3, Cyclopropyl, CF3, F, Br, Cl, I, ethyl, -CH2CF3, isopropyl, tert-butyl, -CH2CN -CN, -OH, -OCH3 Deuterium, CHF2, Alternatively, two R8 atoms connected to the same carbon atom may cyclize into a cyclopropyl group;

[0649] n is selected from 0, 1, 2, and 3.

[0650] In some embodiments of this application, the compound or its stereoisomers, or pharmaceutically acceptable salts, are characterized in that the compound is selected from the following structures:

[0651] Wherein, R4, R8, ring B, and n are as defined in any technical solution of this application.

[0652] In some embodiments of this application, the compound or its stereoisomers, or pharmaceutically acceptable salts, are characterized in that the compound is selected from the following structures:

[0653] Wherein, R4, R8, ring B, and n are as defined in any technical solution of this application.

[0654] In some embodiments of this application, the compound or its stereoisomers, or pharmaceutically acceptable salts, are characterized in that the compound is selected from the following structures:

[0655] Among them, R4 is selected from C 3-8 cycloalkyl and C 1-6 Alkyl; preferably, R4 is selected from cyclopropyl and methyl; more preferably, R4 is methyl;

[0656] Ring B is a 5-6 membered heteroaryl group containing 1-3 nitrogen atoms; preferably, ring B is...

[0657] R8 is selected from hydrogen, deuterium, and C. 1-4 Alkyl, -C(=O)NR 7a R 7b -C 1-4 Alkyl C(=O)NR 7a R 7b -C(=O)R 7a -C(=O)OR 7a C 3-8 Cycloalkyl, 3-8 membered heterocyclic, 5-8 membered heteroaryl, C 1-4 Halogenated alkyl, halogen, hydroxyl, cyano, C 1-6 Hydroxyalkyl and C 1-6 Alkoxy, of which, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, 5-8 membered heteroaryl and C 1-4 The alkyl group is optionally substituted, and the substituent is selected from deuterium, halogen, amino, hydroxyl, cyano, C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1- 6-Deuterated Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 One or more of cycloalkyl and 3-8 membered heterocyclic alkyl groups; or two R8s attached to the same carbon atom can cyclize to C. 3-8 cycloalkyl; wherein R 7a R 7b Each is independently selected from hydrogen, C 1-4 Haloalkyl, C 1-6 Alkyl, C 3-8 Cycloalkyl and 3-8 membered heterocycloalkyl, wherein the C 3-8 Cycloalkyl and 3-8 membered heterocycloalkyl groups may optionally be substituted with one or more groups selected from the following: deuterium, halogen, amino, hydroxyl, cyano, C 1-4 Alkyl, C1-4 Haloalkyl, C 1-4 Hydroxyalkyl and C 1-4 Alkyl group; preferably, R8 is selected from hydrogen, CH3, Cyclopropyl, CF3, F, Br, Cl, I, ethyl, -CH2CF3, isopropyl, tert-butyl, -CH2CN -CN, -OH, -OCH3 Deuterium, CHF2, Alternatively, two R8 atoms connected to the same carbon atom may cyclize into a cyclopropyl group;

[0658] n is selected from 0, 1, 2, and 3.

[0659] In some embodiments of this application, the compound or its stereoisomers, or pharmaceutically acceptable salts, are characterized in that the compound is selected from the following structures:

[0660] Wherein, R4, R8, ring B, and n are as defined in any technical solution of this application.

[0661] In some embodiments of this application, the compound or its stereoisomers, or pharmaceutically acceptable salts, are characterized by being selected from the following structures:

[0662] Wherein, R4, R8, ring B, and n are as defined in any technical solution of this application.

[0663] In some embodiments of this application, the compound or its stereoisomers, or pharmaceutically acceptable salts, are characterized in that the compound is selected from the following structures:

[0664] Wherein, R4, R8, and n are as defined in any technical solution of this application.

[0665] In some embodiments of this application, the compound or its stereoisomers, or pharmaceutically acceptable salts, are characterized in that the compound is selected from the following structures:

[0666] Wherein, R4, R8, and n are as defined in any technical solution of this application.

[0667] In some embodiments of this application, the compound or its stereoisomers, or pharmaceutically acceptable salts, are characterized in that the compound is selected from the following structures:

[0668] Among them, R4 is selected from C 3-8 cycloalkyl and C 1-6 Alkyl; preferably, R4 is selected from cyclopropyl and methyl; more preferably, R4 is methyl;

[0669] R8 is selected from hydrogen, deuterium, and C. 1-4 Alkyl, -C(=O)NR 7a R 7b -C 1-4 Alkyl C(=O)NR 7a R 7b -C(=O)R 7a -C(=O)OR 7a C 3-8 Cycloalkyl, 3-8 membered heterocyclic, 5-8 membered heteroaryl, C 1-4 Halogenated alkyl, halogen, hydroxyl, cyano, C 1-6 Hydroxyalkyl and C 1-6 Alkoxy, of which, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, 5-8 membered heteroaryl and C 1-4 The alkyl group is optionally substituted, and the substituent is selected from deuterium, halogen, amino, hydroxyl, cyano, C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1- 6-Deuterated Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 One or more of cycloalkyl and 3-8 membered heterocyclic alkyl groups; or two R8s attached to the same carbon atom can cyclize to C. 3-8 cycloalkyl; wherein R 7a R 7b Each is independently selected from hydrogen, C 1-4 Haloalkyl, C 1-6 Alkyl, C 3-8 Cycloalkyl and 3-8 membered heterocycloalkyl, wherein the C 3-8 Cycloalkyl and 3-8 membered heterocycloalkyl groups may optionally be substituted with one or more groups selected from the following: deuterium, halogen, amino, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Hydroxyalkyl and C 1-4 Alkyl group; preferably, R8 is selected from hydrogen, CH3, Cyclopropyl, CF3, F, Br, Cl, I, ethyl, -CH2CF3, isopropyl, tert-butyl, -CH2CN -CN, -OH, -OCH3 Deuterium, CHF2, Alternatively, two R8 atoms connected to the same carbon atom may cyclize into a cyclopropyl group;

[0670] n is selected from 0, 1, 2, and 3.

[0671] This application provides a compound or its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein the compound is any one of the following:

[0672] This application provides a compound or its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein the compound is any one of the following:

[0673] This application provides a compound or its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein the compound is any one of the following:

[0674] This application provides a compound or its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein the compound is any one of the following:

[0675] This application provides a compound or its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein the compound is any one of the following:

[0676] This application provides a compound or its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein the compound is any one of the following:

[0677] This application provides a compound or its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein the compound is any one of the following:

[0678] This application provides a compound or its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein the compound is any one of the following:

[0679] This application provides a compound or its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein the compound is any one of the following:

[0680] This application provides a compound or its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein the compound is any one of the following:

[0681] This application provides a compound or its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein the compound is any one of the following:

[0682] This application provides a compound or its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein the compound is any one of the following:

[0683] This application provides a compound or its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein the compound is any one of the following:

[0684] This application provides a compound or its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein the compound is any one of the following:

[0685] This application provides a compound or its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein the compound is any one of the following:

[0686] This application provides a compound or its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein the compound is any one of the following:

[0687] This application provides a compound or its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein the compound is any one of the following:

[0688] This application provides a compound or its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein the compound is any one of the following:

[0689] This application provides a compound or its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein the compound is any one of the following:

[0690] This application provides a compound or its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein the compound is any one of the following:

[0691] This application provides a compound or its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein the compound is any one of the following:

[0692] This application provides a compound or its stereoisomer, or a pharmaceutically acceptable salt thereof, wherein the compound is any one of the following:

[0693] This application provides a pharmaceutical composition comprising the above-described compound or its stereoisomer, a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier.

[0694] In some embodiments of this application, the content of the compound or its stereoisomer or its pharmaceutically acceptable salt in the pharmaceutical composition is 0.1 mg to 1000 mg.

[0695] In some embodiments of this application, the pharmaceutically acceptable carrier in the pharmaceutical composition includes one or more of fillers, disintegrants, binders, flow aids, and lubricants.

[0696] This application provides the use of the above-described compound or its isomers, pharmaceutically acceptable salts, or the above-described pharmaceutical compositions in the preparation of a medicament for treating cancer.

[0697] This application provides the use of the above-described compound or its isomers, pharmaceutically acceptable salts, or the above-described pharmaceutical compositions in the preparation of a medicament for treating PLK4-mediated cancer.

[0698] This application provides a method for treating PLK4-mediated cancer, comprising administering to a patient a therapeutically effective amount of the above-described compound or its stereoisomer, a pharmaceutically acceptable salt, or the above-described pharmaceutical composition.

[0699] This application provides the above-described compound or its stereoisomers, pharmaceutically acceptable salts, or the above-described pharmaceutical compositions for the treatment of PLK4-mediated cancer.

[0700] In some embodiments of this application, the aforementioned cancers are selected from lung cancer, small cell lung cancer, non-small cell lung cancer, breast cancer, colon cancer, brain cancer, pharyngeal cancer, nasopharyngeal cancer, oropharyngeal cancer, head and neck cancer, neuroblastoma, prostate cancer, melanoma, glioblastoma multiforme, ovarian cancer, cervical cancer, lymphoma, leukemia, sarcoma, cancer with tumor effects, osteosarcoma, germ cell tumor, glioma or mesothelioma, and soft tissue cancer.

[0701] This application provides the following compounds or their stereoisomers, and pharmaceutically acceptable salts:

[0702] Wherein, X is a halogen, selected from fluorine, chlorine, bromine and iodine;

[0703] Each PG1 group is independently protected by either a hydrogen or an amino group. The amino protecting group can be an alkoxycarbonyl group, such as benzyloxycarbonyl (Cbz), tert-butyloxycarbonyl (Boc), methoxycarbonyl (Fmoc), allyloxycarbonyl (Alloc), trimethylsilylethoxycarbonyl (Teoc), or methoxycarbonyl (or ethoxycarbonyl); or an acyl group, such as phthaloyl (Pht), p-toluenesulfonyl (Tos), or trifluoroacetyl (Tfa). , o-(p-)nitrobenzenesulfonyl (Ns), p-valeryl, benzoyl, tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, allyloxycarbonyl, trichloroethoxycarbonyl, trimethylsilylethoxycarbonyl, benzyloxycarbonyl, p-methylbenzenesulfonyl, p-nitrobenzenesulfonyl, trifluoroacetyl, methoxycarbonyl or ethoxycarbonyl; alkyl amino protecting groups, such as triphenylmethyl (Trt), 2,4-dimethoxybenzyl (Dmb), 4-methoxybenzyl (PMB) or benzyl (Bn);

[0704] Rx is independently selected from hydrogen and C. 1-4 alkyl.

[0705] This application provides the following compounds or their stereoisomers, and pharmaceutically acceptable salts, selected from:

[0706] Technical effect

[0707] The compound of this application has good PLK4 kinase inhibitory activity, good cellular activity, and selectivity.

[0708] Explanation and Definition

[0709] Unless otherwise stated, the following terms and phrases used herein are intended to have the following meanings. A particular term or phrase should not be considered uncertain or unclear unless specifically defined, but should be understood in its ordinary sense.

[0710] The term "pharmaceutically acceptable" refers to compounds, materials, compositions, and / or dosage forms that are suitable for use in human and animal tissues to the extent of reasonable medical judgment without excessive toxicity, irritation, allergic reactions, or other problems or complications, and that are commensurate with a reasonable benefit / risk ratio.

[0711] The term "pharmaceutically acceptable salt" refers to derivatives obtained from the compounds of this application prepared with relatively non-toxic acids or bases. These salts can be prepared during the synthesis, isolation, and purification of the compounds, or by reacting the purified free form of the compounds with suitable acids or bases. When the compounds contain relatively acidic functional groups, they react with alkali metal, alkaline earth metal hydroxides, or organic amines to yield base addition salts, including alkali metal and alkaline earth metal-based cations, as well as non-toxic ammonium, quaternary ammonium, and amine cations, and also encompassing amino acid salts. When the compounds contain relatively basic functional groups, they react with organic or inorganic acids to yield acid addition salts.

[0712] The term "pharmaceutically acceptable carrier" refers to a medium generally acceptable in the art for delivering a bioactive pharmaceutical agent to animals, particularly mammals. Depending on the route of administration and dosage form, this includes, for example, adjuvants, excipients, or excipients such as diluents, preservatives, fillers, flow modifiers, disintegrants, wetting agents, emulsifiers, suspending agents, sweeteners, flavoring agents, aromatizers, antibacterial agents, antifungal agents, lubricants, and dispersants. Pharmaceutically acceptable carriers are formulated based on a multitude of factors, within the scope of those skilled in the art. These include, but are not limited to, the type and nature of the formulated active pharmaceutical agent, the recipient to whom the composition containing the pharmaceutical agent is to be administered, the intended route of administration of the composition, and the target therapeutic indication. Pharmaceutically acceptable carriers include both aqueous and non-aqueous media, as well as various solid and semi-solid dosage forms. In addition to the active pharmaceutical agent, such carriers include many different components and additives, and the inclusion of such additional components in the formulation for various reasons (e.g., stabilizing active pharmaceutical agents, binders, etc.) is well known to those skilled in the art.

[0713] The term "effective preventive or therapeutic dose" refers to a sufficient amount of the compound of this application, its pharmaceutically acceptable salts, or its stereoisomers to provide a reasonable benefit / risk ratio for treating any medical condition and / or preventing the disorder. However, it should be understood that the total daily dose of the compound of Formula I, its pharmaceutically acceptable salts, and the composition thereof must be determined by the attending physician within the bounds of reliable medical judgment. For any given patient, the specific effective therapeutic dose level must be determined based on a number of factors, including the disorder being treated and its severity; the activity of the specific compound used; the specific composition used; the patient's age, weight, general health condition, sex, and diet; the timing, route of administration, and excretion rate of the specific compound used; the duration of treatment; drugs used in combination with or concurrently with the specific compound used; and similar factors known in the medical field.

[0714] The compounds and their stereoisomers described in this application are all within the scope of this application, including enantiomers, diastereomers, and racemic mixtures.

[0715] The term "enantiomer" refers to stereoisomers that are mirror images of each other.

[0716] The term "diastereomer" refers to a stereoisomer of a molecule that has two or more chiral centers and is not a mirror image of the molecule.

[0717] The stereoisomers of the compounds in this application can be prepared by chiral synthesis, chiral reagents, or other conventional techniques. For example, an enantiomer of a certain compound in this application can be prepared by asymmetric catalysis or chiral derivative derivatization. Alternatively, a single stereoisomer can be obtained from a mixture using chiral resolution techniques. Alternatively, it can be prepared directly from chiral starting materials. The separation of optically pure compounds in this application is typically accomplished using preparative chromatography, employing a chiral column to achieve the separation of chiral compounds.

[0718] The absolute stereoconfiguration of a compound can be confirmed using conventional techniques in the art. For example, single-crystal X-ray diffraction (SFC) can be used, or the absolute configuration of the compound can be confirmed by examining the chiral structure of the starting material and the reaction mechanism of asymmetric synthesis. Alternatively, after resolution, the stereoconfiguration can be determined by comparing it with a product whose absolute configuration is known. Compounds marked "absolute configuration unknown" in this article are typically racemic compounds resolved into single isomers via chiral preparative SFC, followed by characterization and testing.

[0719] The term "optionally" means that something may or may not be substituted, unless otherwise specified. The type and number of substituents can be arbitrary on the basis of what is chemically feasible. For example, the term "optionally substituted with one or more R groups" means... d"Replacement" means that it can be replaced by one or more Rs d Replacement, or not by R d replace.

[0720] When any variable (e.g., R) d When a compound appears more than once in its composition or structure, its definition is independent in each case. For example, This indicates that the cyclopentyl group is surrounded by 3 R groups. d Replaced, and each R d Each has its own independent options.

[0721] When the structure appears When the key is set, it means that the key can be either a double key or a single key.

[0722] When R in L2 c or R d Forming a K-loop with R3, and with structural elements During regeneration, both single and double bonds in the structure can be adjusted according to the regeneration system, such as K-rings and... The reciprocal ring can include the following structure:

[0723] When a substituent's bond can be cross-linked to two atoms on a ring, this substituent can bond to any atom on that ring. For example, structural units. This indicates that the substituent R1 can be substituted at any position on the benzene ring.

[0724] When the listed substituents do not specify which atom they are attached to in a compound included but not specifically mentioned in the general chemical formula, such substituents can be bonded to any of their atoms. For example, pyrazole as a substituent means that any carbon or nitrogen atom on the pyrazole ring is attached to the substituted group; when the structure contains... When, it indicates that the atom is a bonding atom, for example This indicates that the N atom on the morpholine ring is a bonding atom.

[0725] Unless otherwise specified, the term "cycle" refers to a saturated, partially saturated, or unsaturated monocyclic or polycyclic ring, including spirocyclic, fused, or bridged rings. The group derived from a ring by removing a hydrogen atom is called a "cycloyl group," which includes monovalent, divalent (often called a subcyclic), trivalent, and tetravalent rings, with the specific valence depending on the number of substituents attached to the ring. This disclosure no longer specifically distinguishes the valence of the ring in its description of "cycloyl groups." Representative "cycloyl groups" include substituted or unsubstituted cycloalkyl, cycloalkenyl, cycloynyl, heterocyclic alkyl, heterocyclic alkenyl, heterocyclic alkenyl, aryl, or heteroaryl groups. Heterocyclic alkyl, heterocyclic alkenyl, and heterocyclic alkenyl are sometimes collectively referred to as heterocyclic groups. The term "hetero" refers to substituted or unsubstituted heteroatoms and their oxidized forms (also called heteroatomic groups). The heteroatoms are generally selected from N, O, S, and P, and the oxidized forms generally include NO, SO, S(O)2, and P(O). The nitrogen atom may be substituted, i.e., NR (R is H or other substituents defined in the text). The number of atoms on the ring is usually defined as the ring number. For example, "3-6 membered heterocyclic alkyl" refers to a ring consisting of 3-6 atoms arranged in a ring, each ring optionally containing 1 to 3 heteroatoms and / or heteroatomic groups, i.e., N, O, S, NO, SO, S(O)2, P(O), or NR. Each ring is optionally substituted by an R group, R being a group defined in the text.

[0726] Unless otherwise specified, "cycloalkyl" refers to a saturated monocyclic or polycyclic hydrocarbon group. Cycloalkyl is preferably C10. 3-8 Monocycloalkyl, more preferably C 36 Monocycloalkyl groups, examples of which include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Cycloalkyl groups can be fused with a benzene ring, such as benzo[a]C5-6 cycloalkyl groups, including, but not limited to, those with...

[0727] Unless otherwise specified, "cycloalkenyl" refers to one or more double bonds in a "cycloalkyl" group, and the cycloalkenyl group is not aromatic. The carbon atom in the cycloalkenyl group may be further oxidized, forming C(O). The cycloalkenyl group includes "3-8 membered cycloalkenyl", "3-6 membered cycloalkenyl", "3-5 membered cycloalkenyl", and "5-6 membered cycloalkenyl". Specific examples include, but are not limited to, those mentioned above.

[0728] Unless otherwise specified, a "heterocyclic group" refers to a non-aromatic monocyclic or polycyclic ring containing a certain number of heteroatoms and / or heterogroups, which may be saturated or partially saturated. The heteroatoms and / or heterogroups are generally selected from N, O, S, NO, SO, S(O)2, P(O), and NR, wherein the carbon atom in the heterocycle is optionally oxidized to form -C(O)-. The "heterocyclic group" is preferably a 3-8 member monoheterocyclic group, more preferably a 5-6 member monoheterocyclic group. Examples of these monoheterocyclic groups include, but are not limited to, ethylene oxide, tetrahydropyrrole, piperidinyl, piperazine, morpholinyl, tetrahydrofuranyl, tetrahydrothiophene, tetrahydropyranyl, 1,3-dioxolane, and 1,4-dioxane. etc. The "heterocyclic group" mentioned herein may optionally be fused with a benzene ring, such as benzo5-6 membered heterocyclic groups, including but not limited to... The structure; when the heterocyclic group is saturated, it is a heterocyclic alkyl group, preferably a 3-8 membered heterocyclic alkyl group, more preferably a 5-6 membered heterocyclic alkyl group, examples of which include, but are not limited to, 3-8 membered heterocyclic alkyl groups. wait

[0729] Unless otherwise specified, the term "aryl" refers to an unsaturated, usually aromatic, hydrocarbon group, which may be a monocyclic or fused rings, preferably C12. 6-10 Aryl groups, examples of which include, but are not limited to, phenyl and naphthyl groups.

[0730] Unless otherwise specified, the term "heteroaryl" refers to a stable monocyclic or polycyclic aromatic hydrocarbon containing at least one heteroatom or heteroatomic group (N, O, S, NO, SO, S(O)₂, or NR). Preferably, it is a 5- or 6-membered monocyclic heteroaryl. Examples of heteroaryl groups include, but are not limited to, pyrrole, pyrazolyl, imidazolyl, pyrazinyl, oxazolyl, isoxazolyl, thiazolyl, furanyl, thiophene, pyridinyl, and pyrimidinyl.

[0731] Unless otherwise specified, the term "fused ring group" refers to a saturated or partially saturated non-aromatic cyclic group formed by two or more carbon rings sharing two adjacent atoms, wherein the ring carbon atoms can be further oxidized to form C(O). The fused ring group includes 5-12 membered fused ring groups, preferably 9-10 membered fused ring groups, such as benzo[a]C. 5-6 cycloalkyl, C 5-6 cycloalkyl-C 5-6 cycloalkyl, 5-6 membered cycloalkenyl benzo[C] 5-6 cycloalkyl groups, benzo[a]C 5-6 Cycloalkyl groups include, but are not limited to,

[0732] Unless otherwise specified, the term "fused heterocyclic group" refers to a saturated or partially saturated non-aromatic cyclic group formed by two or more cyclic structures sharing two adjacent atoms, containing at least one heteroatom in the ring; the heteroatom is generally selected from N, O, and S; the cyclic carbon atom and heteroatom in the fused heterocycle can be further oxidized to form a cyclic group containing C(O), NO, SO, or S(O)2 groups, which are also included in the definition of heterocyclic group in this application. The fused heterocyclic group includes 5-12 membered fused heterocyclic groups, preferably 9-10 membered fused heterocyclic groups, such as benzo5-6 membered heterocyclic groups, 5-6 membered heteroaryl-5-6 membered heterocyclic groups, 5-6 membered heteroaryl-5-8 membered heterocyclic groups, 5-6 membered heterocyclic groups, 5-6 membered heterocyclic groups, 5-6 membered heterocyclic groups, benzo5-6 membered saturated heterocyclic groups, and 5-6 membered heteroaryl-5-6 membered saturated heterocyclic groups; specific examples of the fused heterocyclic group include, but are not limited to:

[0733] The text appears In a fused ring structure, when ring B is defined as a heteroaryl group, the shared atom between the two rings can be a carbon atom or a heteroatom. For example, this structure contains...

[0734] Unless otherwise specified, the term "spirocyclic group" refers to a saturated or partially saturated cyclic structure formed by two or more carbon rings sharing a single carbon atom. Optionally, the carbon atom in the cyclic structure may be substituted with oxygen. Specific examples include "5-15 membered spirocyclic groups," "4-11 membered spirocyclic groups," "6-11 membered spirocyclic groups," "5-10 membered spirocyclic groups," "7-10 membered spirocyclic groups," "6-9 membered spirocyclic groups," "7-8 membered spirocyclic groups," and "9-10 membered spirocyclic groups," etc. Specific examples include, but are not limited to:

[0735] Unless otherwise specified, when structural units When M2 is selected from =0, it represents When M3 is selected as =0, it represents

[0736] Unless otherwise specified, the term "spiroheterocyclic group" refers to a saturated or partially saturated cyclic structure derived from the substitution of at least one carbon atom in a "spirocyclic group" by a heteroatom / heteroatom group selected from N, O, S, P, NO, SO, S(O)2, P(O), and NR, where R is H or any possible substituent group, and the "spirocyclic group" is as defined above. It includes, but is not limited to, cyclic structures formed from heterocyclic spiroheterocycles and heterocyclic spirocyclic alkanes. The spiroheterocycle preferably contains 1-2 heteroatoms selected from NR and / or O, more preferably 1 NR and 0-1 NR or O heteroatoms. The spiroheterocycle is preferably a "nitrogen-containing spiroheterocycle," which refers to a spiroheterocycle with at least one NR ring atom. The spiroheterocycle includes 7-11 membered spiroheterocycles, 7-9 membered spiroheterocycles, 7-11 membered nitrogen-containing spiroheterocycles, and 7-9 membered nitrogen-containing spiroheterocycles. Specific examples include, but are not limited to: wait.

[0737] Unless otherwise specified, the term "bridged ring group" refers to a saturated or partially saturated ring structure formed by two or more carbon rings sharing two non-adjacent carbon atoms. Optionally, the carbon atoms in the ring structure may be substituted with oxygen. "Bridged ring groups" include, for example, "5-11-membered bridged ring groups," "6-11-membered bridged ring groups," "5-10-membered bridged ring groups," "7-10-membered bridged ring groups," "6-9-membered bridged ring groups," "7-8-membered bridged ring groups," "9-10-membered bridged ring groups," etc. Specific examples include, but are not limited to:

[0738] Unless otherwise specified, the term "bridged heterocyclic group" refers to a saturated or partially saturated cyclic structure derived from the substitution of at least one carbon atom in the "bridged cyclic group" by a heteroatom / heteroatomic group selected from N, O, S, P, NO, SO, S(O)2, P(O), and NR, where R is H or any possible substituent group, and the "bridged cycloalkyl group" is as defined above. "Bridged heterocyclic groups" include, for example, "5-11-membered bridged heterocyclic groups," "6-11-membered bridged heterocyclic groups," "5-10-membered bridged heterocyclic groups," "7-10-membered bridged heterocyclic groups," "6-9-membered bridged heterocyclic groups," "7-8-membered bridged heterocyclic groups," "9-10-membered heterobridged cyclic groups," "6-10-membered bridged heterocyclic alkenyl groups," "6-8-membered bridged heterocyclic alkenyl groups," "7-8-membered nitrogen-containing bridged heterocyclic alkenyl groups," etc. Preferably, the heteroatoms are independently selected from 1-3 N and / or O atoms. Preferably, the bridging heterocyclic group is a "nitrogen-containing bridging heterocyclic group," meaning that at least one ring atom is N, and optionally contains one or more other heteroatoms; preferably, the "nitrogen-containing bridging heterocyclic group" contains one N atom and 0-2 atoms selected from N and / or O and / or S. Preferably, the "nitrogen-containing bridging heterocyclic group" contains one N atom and 0-1 atoms selected from O and / or S. Preferably, the bridging heterocyclic group is an "oxygen-containing bridging heterocyclic group," meaning that at least one ring atom is O, and optionally contains one or more other heteroatoms; preferably, the "oxygen-containing heterocyclic group" contains one O atom and 0-2 atoms selected from N and / or O. Specific examples include, but are not limited to: wait.

[0739] Unless otherwise specified, the term "alkyl" is used to denote a straight-chain or branched saturated hydrocarbon group. C is preferred. 1-6 Alkyl groups, more preferably C 1-4 Alkyl groups, examples of which include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, pentyl, isopentyl, neopentyl, n-hexyl, etc.

[0740] Unless otherwise specified, the term "alkylene" refers to a group derived from a branched or straight-chain saturated aliphatic alkane by removing two hydrogen atoms, which may originate from the same carbon atom or different carbon atoms; the "alkylene" as used in this disclosure is preferably a "straight-chain alkylene"; the "alkylene" includes "C 1-7 Alkylene, C 2-7 Alkylene, C 3-6 Alkylene, C 3-5"alkylene"; specific examples include, but are not limited to, -CH2-, -CH2CH2-, -CH2CH2CH2-, -CH(CH2)CH2-, -CH2CH2CH2CH2-, -CH(CH2)CH2CH2-, -CH(CH2CH2)CH2-, -C(CH2)(CH2)CH2-, -CH2CH2CH2CH2CH2-, etc. The methylene structural unit in the alkylene chain described in this application may be optionally and independently replaced by groups such as C=C, C≡C, -O-, -S-, -C(O)-, -N(R)-, -Cy-, etc.; any hydrogen atom in the alkylene chain may also be optionally replaced by one or more groups, such as hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-8 quinone heteroaryl, etc.

[0741] Unless otherwise specified, the term "hydroxyalkyl" refers to a group derived from an alkyl group in which one or more hydrogen atoms are replaced by a hydroxyl group, and "hydroxyalkyl" as used in this disclosure includes "hydroxyl C". 1-6 Alkyl group, hydroxyl group 1-4 Alkyl groups; specific examples include, but are not limited to, -CH2OH, -CH2CH2OH, -CH(OH)CH3, and -CH2CH2CH2OH. wait.

[0742] Unless otherwise specified, the term "alkoxy" refers to an alkyl group connected by an oxygen bridge, i.e., a group obtained by substituting a hydrogen atom in a hydroxyl group with an alkyl group. Preferably C 1-6 Alkoxy, more preferably C 1-4 Alkoxy groups. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, neopentoxy, and n-hexyloxy.

[0743] Unless otherwise specified, the term "halogen" refers to a fluorine, chlorine, bromine, or iodine atom.

[0744] Unless otherwise specified, the term "haloalkyl" refers to an alkyl group in which one or more hydrogen atoms are replaced by halogen atoms. C is preferred. 1-6 Halogenated alkyl, more preferably C1-4 Haloalkyl groups. Examples of haloalkyl groups include, but are not limited to, monofluoromethyl, difluoromethyl, trifluoromethyl, trichloromethyl, tribromomethyl, 1,1,1-trifluoroethyl, 2,2,2-trifluoroethyl, 2,2,2-trichloroethyl, etc.

[0745] Unless otherwise specified, the term "haloalkoxy" refers to a group obtained by substituting one or more hydrogen atoms in an alkoxy group with a halogen. Preferably, the "haloalkoxy" described in this disclosure is "haloC". 1-6 Alkoxy, halogenated C 1-4 Alkyl groups. Specific examples described in this disclosure include: fluoromethoxy groups (including monofluoromethoxy, difluoromethoxy, and trifluoromethoxy), -OCH2CF3, -OCHFCH3, etc. Alkyl groups are as defined above.

[0746] Unless otherwise specified, the term "alkenyl" refers to a group derived from a straight-chain or branched alkene (containing at least one carbon-carbon double bond) by removing one hydrogen atom, including "C". 2- 6-alkenyl", C 2-5 "alkenyl", "C" 2-4 "alkenyl", "C" 2-3 "Alkenyl", specific examples include but are not limited to: -CH=CH2, -CH=CHCH3, -C(CH2)=CH2, -CH=CHCH2CH3, -CH2CH=CHCH3, etc.

[0747] Unless otherwise specified, the term "alkynyl" refers to a group derived from a straight-chain or branched alkyne (containing at least one carbon-carbon triple bond) by removing one hydrogen atom, including "C". 2- 5-acetylinyl group, C 2-4 "Alkyne", "C" 2-3 "Alkyne group", specific examples include but are not limited to: -C≡CH, -C≡CHCH3, HC≡CHCH2-, HC≡CC≡C-, etc.

[0748] In particular, all combinations of substituents and / or their variants are permitted only if such combinations produce stable compounds.

[0749] The preparation methods for some compounds in this application reference the preparation methods for the aforementioned similar compounds. Those skilled in the art should understand that when using or referring to the referenced preparation methods, the reactant ratios, reaction solvents, reaction temperatures, etc., can be appropriately adjusted according to the different reactants.

[0750] The compounds of this application can be prepared by a variety of synthetic methods known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthetic methods, and equivalent substitutions known to those skilled in the art. Preferred embodiments include, but are not limited to, the embodiments of this application. Attached Figure Description

[0751] Figure 1 shows a ball-and-stick model of the INT-P2 molecule. Detailed Implementation

[0752] The present invention will be described in detail below with reference to embodiments, but this does not imply any adverse limitation on the invention. The present invention has been described in detail, and specific embodiments thereof have been disclosed. It will be apparent to those skilled in the art that various changes and modifications can be made to the specific embodiments of the present invention without departing from the concept and scope of the invention.

[0753] The structures of the compounds in this application were determined by nuclear magnetic resonance (NMR) and / or liquid chromatography-mass spectrometry (LC-MS), or ultra-high performance liquid chromatography-mass spectrometry (UPLC-MS). NMR chemical shifts (δ) are given in parts per million (ppm). NMR determinations were performed using a Bruker Neo 400M or Bruker Ascend 400 NMR spectrometer, with solvents including deuterated dimethyl sulfoxide (DMSO-d6), deuterated methanol (CD3OD), and deuterated chloroform (CDCl3), heavy water (D2O), and tetramethylsilane (TMS) as the internal standard.

[0754] The starting materials used in the embodiments of this application are known and commercially available, or can be synthesized using methods known in the art.

[0755] Unless otherwise specified, all reactions in this application are carried out under continuous magnetic stirring, in a dry nitrogen or argon atmosphere, using a dry solvent, and the reaction temperature is in degrees Celsius.

[0756] General preparation method:

[0757] Wherein, M1, M2, M3, R4, R5, R6, R7, R8, ring A, ring B, m, and n are as defined in any technical solution of this application.

[0758] Specific representative preparation methods:

[0759] Preparation Examples

[0760] Example 1:

[0761] 3-(5-cyclopropyl-6-((5-cyclopropen-1H-pyrazol-3-yl)amino)-2-((2,6-difluoro-4-(methylsulfonyl)phenyl)(methyl)amino)pyrimidin-4-yl)-5-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazaphen-4-one

[0762] Reaction route:

[0763] Operating steps:

[0764] Step A: Methyl 4-bromo-1H-pyrazole-3-carboxylate (10 g, 48.78 mmol) and 3-(methylamino)prop-1-ol (6.52 mg, 73.17 mmol) were dissolved in ultra-dry dimethyltetrahydrofuran (100 mL), cooled to 0 °C, and sodium tert-butoxide (48 mL, 97.56 mmol) was added to the above reaction solution. The mixture was stirred at 50 °C for 3 hours.

[0765] After the reaction was completed, the reaction solution was filtered, the filtered solid was dissolved in water, the pH was adjusted to 7 with citric acid, and the solution was extracted with dichloromethane / methanol (volume ratio = 10 / 1, 300 mL x 4 times). The organic phase was collected, dried with anhydrous sodium sulfate, filtered, and concentrated to obtain 6.3 g of 4-bromo-N-(3-hydroxypropyl)-N-methyl-1H-pyrazole-3-carboxamide.

[0766] MS(ESI)M / Z: 262.1 [M+H] + .

[0767] 1 H NMR (400MHz, DMSO-d6): δ7.99 (s, 1H), 3.50-3.46 (m, 2H), 3.36-3.30 (m, 3H), 2.96-2.91 (m, 3H), 1.72-1.62 (m, 2H)

[0768] Step B: Dissolve 4-bromo-N-(3-hydroxypropyl)-N-methyl-1H-pyrazole-3-carboxamide (6.2 g, 23.66 mmol) and triphenylphosphine (12.4 g, 47.32 mmol) in ultra-dry tetrahydrofuran (80 mL). After cooling the reaction solution to 0 °C and stirring for 10 minutes, add DIAD (7 mL, 35.49 mmol) to the above reaction solution and react at room temperature for 1 hour.

[0769] The reaction was monitored by LCMS until it was complete. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain 5.02 g of 3-bromo-5-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazazo-4-one.

[0770] MS(ESI)M / Z: 244.0 [M+H] + .

[0771] 1 H NMR (400MHz, DMSO-d6): δ7.62 (s, 1H), 4.37-4.33 (m, 2H), 3.30-3.26 (m, 2H), 3.05 (s, 3H), 2.20-2.14 (m, 2H).

[0772] Step C: Dissolve 3-bromo-5-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazaphen-4-one (920 mg, 3.77 mmol) and Pin2B2 (2.87 g, 11.31 mmol) in ultra-dry dioxane (10 mL). Add potassium acetate (740 mg, 7.54 mmol), Pd(dppf)Cl2 (85 mg, 0.38 mmol), and palladium acetate (85 mg, 0.38 mmol) to the above reaction solution in sequence. After purging with nitrogen, heat the reaction system to 110 °C and react overnight.

[0773] LCMS showed the consumption of raw materials. The reaction solution was cooled to room temperature and then filtered. The filter cake was washed with dichloromethane, the filtrate was collected and concentrated, and the residue was purified by silica gel column chromatography to obtain 530 mg of (5-methyl-4-oxo-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazaphen-3-yl)boronic acid.

[0774] MS(ESI)M / Z: 210.3[M+H] + .

[0775] Step D: Dissolve tert-butyl 5-amino-3-cyclopropyl-1H-pyrazole-1-carboxylate (300 mg, 1.35 mmol) and 4,6-dichloro-5-cyclopropyl-2-(methylthio)pyrimidine (316 mg, 1.35 mmol) in ultra-dry tetrahydrofuran (10 mL). Then, cool the reaction solution to 0 °C and slowly add sodium bis(trimethylsilylamino) (1.5 mL, 2.97 mmol) to the above mixture. Then stir at 0 °C for 1 hour.

[0776] After the reaction was completed, the reaction solution was quenched in a saturated ammonium chloride solution (20 mL), extracted with ethyl acetate (50 mL x 3 times), and washed with saturated brine (20 mL x 3 times). The organic phase was dried and concentrated, and the residue was purified by silica gel column chromatography to obtain 350 mg of 6-chloro-5-cyclopropyl-N-(5-cyclopropyl-1H-1,2,4-triazol-3-yl)-2-(methylthio)pyrimidine-4-amine.

[0777] MS(ESI)M / Z: 322.1[M+H] + .

[0778] Step E: Dissolve 6-chloro-5-cyclopropyl-N-(5-cyclopropyl-1H-1,2,4-triazol-3-yl)-2-(methylthio)pyrimidine-4-amine (350 mg, 0.108 mmol) in acetonitrile (10.0 mL), then add cesium carbonate (3.53 g, 10.85 mmol) to the above solution. After stirring for 10 minutes, add p-methoxybenzyl chloride (840 mg, 5.43 mmol) to the above reaction solution and stir overnight at room temperature.

[0779] The reaction was monitored by LCMS until completion. The reaction solution was poured into saturated saline (20 mL), extracted with dichloromethane (50 mL × 3 times), collected, dried and concentrated, and the residue was purified by silica gel column chromatography to obtain 400 mg of 6-chloro-5-cyclopropyl-N-(5-cyclopropyl-1-(4-methoxybenzyl)-1H-pyrazol-3-yl)-N-(4-methylthiobenzyl)-2-(methylthio)pyrimidine-4-amine.

[0780] MS(ESI)M / Z: 562.2 [M+H] + .

[0781] Step F: 6-Chloro-5-cyclopropyl-N-(5-cyclopropyl-1-(4-methoxybenzyl)-1H-pyrazol-3-yl)-N-(4-methylthiobenzyl)-2-(methylthio)pyrimidine-4-amine (400 mg, 0.69 mmol) was dissolved in tetrahydrofuran (5.0 mL) and ethyl acetate (5.0 mL). Then, sodium tungstate dihydrate (46 mg, 0.139 mmol) and tetrabutylammonium hydrogen sulfate (46 mg, 0.139 mmol) were added to the above solution. After stirring at room temperature for 10 minutes, hydrogen peroxide (0.43 mL, 13.86 mmol) was added to the reaction solution, and the temperature was raised to 50 °C and stirred for 1 hour.

[0782] The reaction was monitored by LCMS to indicate completion. The reaction solution was poured into water (20 mL) and extracted with ethyl acetate (50 mL x 3 times). The organic phase was washed with saturated brine (20 mL x 3 times), dried, and concentrated to obtain 370 mg of 6-chloro-5-cyclopropyl-N-(5-cyclopropyl-1-(4-methoxybenzyl)-1H-pyrazol-3-yl)-N-(4-methylthiobenzyl)-2-(methylsulfonyl)pyrimidine-4-amine.

[0783] MS(ESI)M / Z: 594.6 [M+H] + .

[0784] Step G: Dissolve 2,6-difluoro-4-(methanesulfonyl)aniline (150 mg, 0.74 mmol) in dry N,N-dimethylpropenylurea (10.0 mL). Then, add sodium bis(trimethylsilylamino)amine (0.28 mL, 1.36 mmol) to the above solution at 0 °C. After stirring for 10 minutes, add a solution of 6-chloro-5-cyclopropyl-N-(5-cyclopropyl-1-(4-methoxybenzyl)-1H-pyrazol-3-yl)-N-(4-methylthiobenzyl)-2-(methanesulfonyl)pyrimidin-4-amine (370 mg, 0.62 mmol) in N,N-dimethylpropenylurea (10.0 mL) to the reaction solution. After stirring at room temperature for 1 hour, add methyl iodide (440 mg, 3.1 mmol) to the reaction solution and stir at room temperature for 30 minutes. 2

[0785] The reaction was monitored by LCMS until completion. The reaction solution was poured into a saturated ammonium chloride solution (50 mL), extracted with ethyl acetate (100 mL × 3 times), and the organic phase was washed with saturated brine (30 mL × 3 times). The organic phase was concentrated, and the residue was purified by silica gel column chromatography to obtain 240 mg of 6-chloro-5-cyclopropyl-N. 4 -(5-Cyclopropyl-1-(4-Methoxybenzyl)-1H-pyrazole-3-yl)-N 2 -(2,6-Difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methylthiobenzyl)-N 2 -Methylpyrimidine-2,4-diamine.

[0786] MS(ESI)M / Z: 735.1 [M+H] + .

[0787] 1 H NMR (400MHz, DMSO-d6): δ7.84-7.79 (m, 3H), 7.01 (d, J=8.4Hz, 2H), 6.87-6.77 (m, 6H), 5.86 (d, J=40.0Hz, 2H), 5.17 (s, 2 H), 3.72 (s, 3H), 3.70 (s, 3H), 3.29 (s, 6H), 1.88-1.78 (m, 2H), 0.88-0.83 (m, 4H), 0.39-0.35 (m, 2H), 0.21-0.17 (m, 2H).

[0788] Step H: 6-Chloro-5-cyclopropyl-N 4 -(5-Cyclopropyl-1-(4-Methoxybenzyl)-1H-pyrazole-3-yl)-N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 4 -(4-methylthiobenzyl)-N 22,4-methylpyrimidine-2,4-diamine (190 mg, 0.26 mmol), (5-methyl-4-oxo-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazaphen-3-yl)boronic acid (160 mg, 0.52 mmol), and potassium phosphate (170 mg, 0.78 mmol) were added sequentially to a mixture of dioxane (10 mL) and water (1.0 mL). Then, [1,1′-bis(diphenylphosphine)ferrocene]palladium dichloromethane dichloride complex (38 mg, 0.052 mmol) was added to the reaction mixture. The reaction mixture was placed under a nitrogen atmosphere and heated to 100 °C overnight.

[0789] The reaction was monitored by LCMS until completion. The reaction solution was poured into water (50 mL) and extracted with dichloromethane (50 mL x 3 times). The organic phase was collected, dried, and concentrated. The residue was purified by reversed-phase chromatography to obtain 90 mg of 3-(5-cyclopropyl-6-((5-cyclopropene-1-(4-methoxybenzyl)-1H-pyrazol-3-yl)(4-methylthiobenzyl)amino)-2-((2,6-difluoro-4-(methylsulfonyl)phenyl)(methyl)amino)pyrimidin-4-yl)-5-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazazo-4-one.

[0790] MS(ESI)M / Z: 864.6 [M+H] + .

[0791] Step I: Dissolve 3-(5-cyclopropyl-6-((5-cyclopropene-1-(4-methoxybenzyl)-1H-pyrazol-3-yl)(4-methylthiobenzyl)amino)-2-((2,6-difluoro-4-(methylsulfonyl)phenyl)(methyl)amino)pyrimidin-4-yl)-5-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazazo-4-one (90 mg, 0.10 mmol) in trifluoroacetic acid (30 mL), then heat to 130 °C and stir for 2 days.

[0792] After the reaction was completed, the reaction solution was concentrated under reduced pressure, and the residue was purified by reversed-phase chromatography (system: 0.1% trifluoroacetic acid) to obtain 34.91 mg of 3-(5-cyclopropyl-6-((5-cyclopropene-1H-pyrazol-3-yl)amino)-2-((2,6-difluoro-4-(methanesulfonyl)phenyl)(methyl)amino)pyrimidin-4-yl)-5-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazazo-4-one.

[0793] MS(ESI)M / Z: 622.4 [MH] - .

[0794] 1 H NMR (400MHz, DMSO-d6): δ11.87 (s, 1H), 8.44-8.29 (m, 1H), 7.84 (m, 3H), 5.43 (m, 1H), 4.33 (m, 2H), 3.35 (m, 6H), 3.33 (m, 3H), 3.02 (m, 2H), 2.20 (m, 2H), 1.80-1.59 (m, 2H), 0.90 (d, J=8.0Hz, 2H), 0.85 (m, 2H), 0.51 (m, 2H), 0.11 (m, 2H).

[0795] Example 2:

[0796] 5-Cyclopropyl-N 4 -(5-Cyclopropyl-1H-pyrazole-3-yl)-N 2 -(2,6-difluoro-4-(methylsulfonyl)phenyl)-N 2 -Methyl-7-(1-methyl-1H-imidazol-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-2,4-diamine

[0797] Reaction route:

[0798] Operating steps:

[0799] Step A: Copper acetate (4.83 g, 26.59 mmol) and 2,2′-bipyridine (4.15 g, 26.59 mmol) were added sequentially to a stirred suspension of 2,4-dichloro-5H-pyrrolo[3,2-d]pyrimidine (5 g, 26.59 mmol), cyclopropylboronic acid (4.57 g, 53.18 mmol), and sodium carbonate (5.64 g, 53.18 mmol) in dichloroethane (90 mL) under oxygen protection. The reaction mixture was heated to reflux and stirred overnight.

[0800] The reaction was monitored by TLC until completion. The reaction mixture was cooled to room temperature and filtered through diatomaceous earth, then washed with dichloromethane (100 mL). The filtrate was then washed with 1N HCl (50 mL), the organic layer was washed with saturated brine (60 mL × 2 times), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography to obtain 2.3 g of 2,4-dichloro-5-cyclopropyl-5H-pyrrolo[3,2-d]pyrimidine.

[0801] MS(ESI) M / Z: 228.0 [M+H] + .

[0802] 1H NMR (400MHz, CDCl3): δ7.55 (d, J=3.3Hz, 1H), 6.57 (d,J=3.3Hz, 1H), 3.77-3.66 (m, 1H), 1.28-1.21 (m, 2H), 1.21-1.14 (m, 2H).

[0803] Step B: At 0 °C, NIS (2.09 g, 9.30 mmol) was slowly added to a DMF (30 mL) solution of 2,4-dichloro-5-cyclopropyl-5H-pyrrolo[3,2-d]pyrimidine (2.02 g, 8.86 mmol). The mixture was stirred at room temperature for 16 h.

[0804] After the reaction was complete as indicated by LCMS, the reaction mixture was diluted with ethyl acetate (100 mL), washed with saturated brine (100 mL × 3 times), dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel column chromatography to give 2.3 g of 2,4-dichloro-5-cyclopropyl-7-iodo-5H-pyrrolo[3,2-d]pyrimidine.

[0805] MS(ESI)M / Z: 353.8 [M+H] + .

[0806] 1 H NMR (400MHz, DMSO-d6): δ8.29 (s, 1H), 3.83 (m, 1H), 1.27-1.20 (m, 2H), 1.13 (m, 2H).

[0807] Step C: To a solution of 2,4-dichloro-5-cyclopropyl-7-iodo-5H-pyrrolo[3,2-d]pyrimidine (1 g, 2.83 mmol) in dioxane (20 mL), 1-methyl-4-(tributyltin)-1H-imidazolium (1.16 g, 3.11 mmol) and Pd(PPh3)4 (330 mg, 0.28 mmol) were added. The reaction was protected with nitrogen and finally stirred at 60 °C for 16 hours.

[0808] The reaction solution was poured into water (50 mL), extracted with ethyl acetate (60 mL × 3 times), the combined organic phases were dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain 700 mg of 2,4-dichloro-5-cyclopropyl-7-(1-methyl-1H-imidazol-4-yl)-5H-pyrrolo[3,2-d]pyrimidine.

[0809] MS(ESI)M / Z: 308.1 [M+H] + .

[0810] Step D: At room temperature, sodium bis(trimethylsilyl)amino (2M, 2.5mL) was slowly added to a tetrahydrofuran (10mL) solution of 2,4-dichloro-5-cyclopropyl-7-(1-methyl-1H-imidazol-4-yl)-5H-pyrrolo[3,2-d]pyrimidine (700mg, 2.27mmol) and 5-cyclopropyl-1-tetrahydropyran-2-ylpyrazole-3-amine (470.50mg, 2.27mmol). The reaction mixture was stirred at room temperature for 1 hour.

[0811] The reaction solution was poured into a saturated ammonium chloride (100 mL) solution and extracted with dichloromethane (100 mL x 3 times). The combined organic phases were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 500 mg of 2-chloro-5-cyclopropyl-N-(5-cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-7-(1-methyl-1H-imidazol-4-yl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine.

[0812] MS(ESI)M / Z: 479.3 [M+H] + .

[0813] 1 H NMR (400MHz, DMSO-d6): δ8.71 (s, 1H), 7.81 (s, 1H), 7.59 (s, 1H), 7.53 (d, J=1.0Hz, 1H), 6.2 3 (s, 1H), 5.44 (dd, J = 8.9, 2.4Hz, 1H), 3.97 (d, J = 3.9Hz, 1H), 3.80 (d, J = 11.5Hz, 1H), 3.71 ( s, 3H), 3.64-3.56 (m, 1H), 2.21 (dt, J=16.4, 8.3Hz, 1H), 1.98-1.88 (m, 3H), 1.56 (dd, J=26. 7, 9.8Hz, 4H), 1.31-1.26 (m, 1H), 1.21-1.15 (m, 2H), 0.90-0.85 (m, 2H), 0.69-0.64 (m, 2H).

[0814] Step E: Cesium carbonate (821.07 mg, 2.52 mmol) and 4-methoxybenzyl chloride (263.10 mg, 1.68 mmol) were added sequentially to a solution of 2-chloro-5-cyclopropyl-N-(5-cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-7-(1-methyl-1H-imidazol-4-yl)-5H-pyrrolo[3,2-d]pyrimidine-4-amine (400 mg, 0.84 mmol) in acetonitrile (10 mL). The mixture was stirred at 25 °C for 12 h.

[0815] LCMS showed the formation of a product peak. The reaction solution was filtered, the filter cake was washed with dichloromethane, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain 150 mg of 6-chloro-5-cyclopropyl-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylthio)pyrimidine-4-amine.

[0816] MS(ESI)M / Z: 599.5 [M+H] + .

[0817] 1 H NMR (400MHz, DMSO-d6): δ7.73(s, 1H), 7.58(d, 1H), 7.54(d, 1H), 7.37(d, 2H), 6.88(d,2H),5.76(s,1H),5.24(d,1H),4.98(d,1H),4.69(d,1H),3.70(d,6H) ,3.53(d,1H),2.74(m,1H),2.27-2.19(m,1H),2.16-2.03(m,1H),1.77(m,2H) , 1.37-1.19(m, 4H), 0.91-0.77(m, 5H), 0.76-0.69(m, 1H), 0.58-0.48(m, 2H).

[0818] Step F: 2,6-Difluoro-4-methylsulfonylaniline (91.17 mg, 0.44 mmol) and 6-chloro-5-cyclopropyl-N-(4-methoxybenzyl)-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-2-(methylthio)pyrimidine-4-amine (130 mg, 0.22 mmol) were dissolved in dioxane (5 mL), cesium carbonate (215.04 mg, 0.66 mmol) and XPhos Pd G3 (18.62 mg, 0.022 mmol) were added, and after nitrogen purging, the mi...

Claims

1. The compound represented by formula (IB) or its stereoisomers, and pharmaceutically acceptable salts thereof. in, M1is selected from the group consisting of N, O, NR1, and CR1; each R1is independently selected from the group consisting of hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 deuteroalkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 alkylthio, C 1-6 haloalkoxy, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, 3-8 membered heterocyclyl, C 6-10 aryl, and 5-8 membered heteroaryl, said hydroxyl, amino, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 deuteroalkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 alkylthio, C 1-6 haloalkoxy, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, 3-8 membered heterocyclyl, C 6-10 aryl, and 5-8 membered heteroaryl are optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, amino, hydroxyl, cyano, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 deuteroalkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 3-8 cycloalkyl, and 3-8 membered heterocycloalkyl; M2 is selected from N, CR2, and =O; R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6- 10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups; M3 is selected from N, CR3, and =O; R3 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6- 10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups; M4 is selected from N or C; R4 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, =O, C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups; R5 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1- 6-Hydroalkoxy, C 3-8 Substituted by one or more substituents in cycloalkyl and 3-8 membered heterocycloalkyl groups; L is selected from -NR6-, -CR6R6-, and -C(=O)-, and R6 is independently selected from hydrogen, C, etc. 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups and C 3-8 cycloalkyl-O-, wherein the C is said to be cycloalkyl-O-, 3-8 The cycloalkyl group may optionally be substituted with one or more groups selected from the following: hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Hydroxyalkyl and C 1-6 Alkyl groups; L1 is selected from NR a CR b and C (=O), where R a Independently selected from hydrogen and C 1-6 Alkyl, R b Selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Halogenated alkyl groups; L2 is a key or selected from NR. c CR d N = CR d CR d =CR d CR c R d -CR c R d O, S and NR c C(=O), where R c Each is independently selected from hydrogen and C. 1-6 Alkyl, R d Each is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, and C. 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Halogenated alkyl groups; Ring A is selected from C 6-10 Aryl, 5-8 membered heteroaryl, 5-12 membered fused-ring group and 5-12 membered heterocyclic group; Ring B does not exist or is selected from C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-8 membered heteroaryl, 5-12 membered fused-ring group and 5-12 membered heterocyclic group; R7 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, sulfur pentafluoride, and -S(=O)2R. 7a -S(=O)2NR 7a R 7b R 7a S(=O)2NR 7b -、-N=S(=O)R 7a R 7b R 7a N = S(=O)(R) 7b )-、-C(=O)NR 7a R 7b -P(=O)R 7a R 7b -P(=O)R 7a NR 7a R 7b C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 The alkyl group is substituted with one or more substituents in the cycloalkyl and 3-8 membered heterocycloalkyl groups; wherein R 7a R 7b Each is independently selected from hydrogen, C 1-6 Alkyl, C 3-8 cycloalkyl and C 1-6 Alkyl groups; R8 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, sulfur pentafluoride, and -S(=O)2R. 7a -S(=O)2NR 7a R 7b R 7a S(=O)2NR 7b -、-N=S(=O)R 7a R 7b R 7a N = S(=O)(R) 7b )-、-C(=O)NR 7a R 7b -C 1-4 Alkyl C(=O)NR 7 aR 7b -P(=O)R 7a R 7b -P(=O)R 7a NR 7a R 7b -C(=O)R 7a -C(=O)OR 7a C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl groups, wherein the hydroxyl, amino, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 The aryl group and the 5-8 heteroaryl group are optionally further selected from deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 The alkyl group is substituted with one or more substituents in the cycloalkyl and 3-8 membered heterocycloalkyl groups; wherein R 7a R 7b Each is independently selected from hydrogen, C 1-4 Haloalkyl, C 1-6 Alkyl, C 3-8 Cycloalkyl and 3-8 membered heterocycloalkyl, wherein the C 3-8 Cycloalkyl and 3-8 membered heterocycloalkyl groups may optionally be substituted with one or more groups selected from the following: deuterium, halogen, amino, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Hydroxyalkyl and C 1-4 Alkyl groups; Alternatively, two R8 atoms attached to the same carbon atom can cyclize into C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic group; or R8 attached to two adjacent carbon atoms co-cyclizes with the attached atoms to form C. 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups; Alternatively, R1 and R4, together with the atoms they are attached to, form a ring C, which is selected from C. 4-8 Cycloalkyl, 4-8 membered heterocyclic, 5-8 membered heteroaryl and C 6-10 Aryl; ring C can be optionally divided by p R 1a Replaced; R 1a Independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or two R atoms attached to the same atom 1a Cycloning to C 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups; or two R groups attached to adjacent atoms 1a The atoms it is connected to together form C 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic groups; m, n, and p are each independently selected from 0, 1, 2, 3, and 4; Alternatively, R1 and R2 together with the atoms they are attached to form an optionally substituted ring D, which is selected from 5-6 membered heterocyclic groups and 5-6 membered heteroaryl groups; Alternatively, R3 and R6, together with the atoms they are attached to, can form an optionally substituted ring E, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 quinone heteroaryl groups; in Ring E is optionally bounded by one or more R 3a Replaced by, R 3a Independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 quinone heteroaryl groups; or, R a or R b R5 and the atoms it is attached to form an optionally substituted ring F, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl and 5-8 membered heteroaryl; in Ring F is optionally bounded by one or more R 4a Replaced by, R 4a Independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3- 8-cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl; or R attached to the same atom 4a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 cycloalkyl or 3-8 membered heterocyclic groups; or, R c or R d R5 and the atoms it is attached to form an optionally substituted ring G, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl and 5-8 membered heteroaryl; in Ring G is optionally divided by one or more R 5a Replaced by, R 5a Independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-8 quinone heteroaryl and -NR 5aa R 5ab ; or R connected to the same atom 5a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 Cycloalkyl or 3-8 membered heterocyclic groups; wherein, R 5aa and R 5ab Each is independently selected from hydrogen or C. 1-4 alkyl; Alternatively, R8 and R5, together with the atoms they are attached to, can form an optionally substituted ring H, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the cyclic H is optionally surrounded by one or more R 6a Replaced by, R 6a Independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl and 5-8 membered heteroaryl; or R attached to the same atom 6a It can form optionally substituted C atoms together with the atoms it is attached to. 3-8 cycloalkyl or 3-8 membered heterocyclic groups; or, R c or R d R3 and the atoms it is attached to form an optionally substituted ring K, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein the ring K is optionally surrounded by one or more R ka Replaced by, R ka Independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or R attached to two adjacent carbon atoms ka The atoms bonded to it together form optionally substituted 5-8 membered heteroaryl groups; or, R3 and R8, together with the atoms they are attached to, form an optionally substituted ring M, which is selected from C. 5-8 cycloalkyl, C 5-8 Cycloalkenyl, 5-8 membered heterocyclic, phenyl, and 5-8 membered heteroaryl; wherein ring M is optionally surrounded by one or more R 8a Replaced by, R 8a Independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or R attached to two adjacent carbon atoms 8a The atoms bonded to it together form optionally substituted 5-8 membered heteroaryl groups; or, Rings B and L are connected by L3, where L3 is an optionally substituted C. 2-7 alkylene chains, the C 2-7 Any methylene unit in the alkylene chain may be optionally and independently replaced by the following groups: C=C, C≡C, -O-, -S-, -C(O)-, -N(R)-. L3a )- or -Cy1-, where R L3a Each is independently selected from hydrogen and C. 1-4 Alkyl, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl and 3-8 membered heterocyclic groups; Cy1 is independently selected from C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-12 heteroaryl, 5-12 fused-ring group, 5-12 fused-ring group, 5-12 spirocyclic group, 5-12 spirocyclic group, 5-12 bridged-ring group and 5-12 bridged-ring group; C 2- Any hydrogen atom in the 7-alkylene chain may optionally be replaced by one or more R L3b Substituted by the group, R L3b Independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Halogenated alkoxy groups, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 aryl and 5-8 membered heteroaryl; or two R groups attached to the same carbon atom L3b It can be cyclicized into C 3-8 cycloalkyl, C 3-8 Cycloalkenyl or 3-8 membered heterocyclic group; wherein the C 1-4 Alkyl, C 3-8 cycloalkyl, C 3-8 Cycloalkenyl, 3-8 membered heterocyclic groups, C 6-10 Aryl, 5-12-membered heteroaryl, 5-12-membered fused-ring, 5-12-membered fused-heterocyclic, 5-12-membered spirocyclic, 5-12-membered spiroheterocyclic, 5-12-membered bridged-ring, and 5-12-membered bridged-ring may optionally be substituted with the following groups: deuterium, halogen, amino, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Halogenated alkyl or C 1-4 Alkyl groups; or structural unit for 2. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in claim 1, characterized in that, R1 is selected from hydrogen, halogens, and C. 1-4 Alkyl and C 1-4 Halogenated alkyl groups.

3. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in claim 2, characterized in that... R1 is selected from hydrogen, fluorine, bromine, chlorine, methyl and trifluoromethyl, with hydrogen being preferred.

4. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-3, characterized in that, M1 is selected from CH, NH, O, N, CF, CCF3, CCH3, CCl and CBr, with CH being preferred.

5. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-4, characterized in that, R4 is selected from =O, C 3-8 cycloalkyl, C 1-6 Alkyl and C 1-6 The haloalkoxy group, preferably, R4 is selected from =O, cyclopropyl, methyl, ethyl, isopropyl, -OCHF2 and -OCF3, and more preferably, R4 is methyl.

6. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-4, characterized in that, R4 is selected from C 3-8 cycloalkyl and C 1-6 Alkyl group, preferably, R4 is selected from cyclopropyl and methyl, and more preferably, R4 is methyl.

7. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-6, characterized in that, R5 is C 3-8 Cycloalkyl, preferably, R5 is cyclopropyl.

8. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-7, characterized in that, L is selected from -N(CH3)-, -NH-, -CH(OCH3)-, -N(OCH3)-, -C(=O)-, -N(CD3)-, Preferably, L is -N(CH3)- or -N(CD3)-, and more preferably, L is -N(CH3)-.

9. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-8, characterized in that, R7 is selected from hydrogen, halogens, sulfur pentafluoride, and -S(=O)2R. 7a R 7a S(=O)2NR 7b - 5-8 membered heterocyclic group, -S(=O)2N 7a R 7b R 7a N = S(=O)(R) 7b )-、-P(=O)R 7a R 7b and -C(=O)NR 7a R 7b The R mentioned therein 7a R 7b Each is independently selected from hydrogen, C 1-6 Alkyl, C 3-8 cycloalkyl and C 1-6 Alkyl group.

10. The compound or its stereoisomers, or pharmaceutically acceptable salts, as described in claim 9, characterized in that, R7 is selected from H, F, SF5, -S(=O)2CH3, CH3S(=O)2NH-, 11. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-10, characterized in that, Ring A is selected from phenyl, benzo5-6 membered heterocyclic groups, and benzoC. 5-6 Cycloalkyl.

12. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in claim 11, characterized in that, Ring A is selected from 13. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-12, characterized in that, Structural unit Selected from Preferred structural unit for 14. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-13, characterized in that, L1 can be -NH-, -CH(NH2)-, -CH(OCH3)-, -N(OCH3)-, or -C(=O)-, for example, NH.

15. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-14, characterized in that, L2 can be a bond, O, S, NH, or -NHC(=O)-.

16. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-15, characterized in that, R8 is selected from hydrogen, deuterium, and C. 1- 4-alkyl, -C(=O)NR 7a R 7b -C 1-4 Alkyl C(=O)NR 7a R 7b -C(=O)R 7a -C(=O)OR 7a C 3-8 Cycloalkyl, 3-8 membered heterocyclic, 5-8 membered heteroaryl, C 1-4 Halogenated alkyl, halogen, hydroxyl, cyano, C 1-6 Hydroxyalkyl and C 1-6 Alkoxy, of which, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, 5-8 membered heteroaryl and C 1-4 The alkyl group is optionally substituted, and the substituent is selected from deuterium, halogen, amino, hydroxyl, cyano, C. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-8 One or more of cycloalkyl and 3-8 membered heterocyclic alkyl groups; or two R8s attached to the same carbon atom can cyclize to C. 3-8 cycloalkyl; wherein R 7a R 7b Each is independently selected from hydrogen, C 1-4 Haloalkyl, C 1-6 Alkyl, C 3-8 Cycloalkyl and 3-8 membered heterocycloalkyl, wherein the C 3-8 Cycloalkyl and 3-8 membered heterocycloalkyl groups may optionally be substituted with one or more groups selected from the following: deuterium, halogen, amino, hydroxyl, cyano, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Hydroxyalkyl and C 1-4 Alkyl groups; And / or, n is selected from 0, 1, 2 and 3.

17. The compound of claim 16 or its stereoisomers, or pharmaceutically acceptable salts, characterized in that, R8 is selected from hydrogen, CH3, etc. Cyclopropyl, CF3, F, Br, Cl, I, ethyl, -CH2CF3, isopropyl, tert-butyl, -CH2CN -CN, -OH, -OCH3 Deuterium, CHF2, Alternatively, two R8 atoms attached to the same carbon atom can cyclize into a cyclopropyl group.

18. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-17, characterized in that, Ring B is selected from phenyl, 5-6-membered heteroaryl, 5-6-membered heteroaryl and 5-8-membered heterocyclic group, C 3-6 cycloalkyl and 3-6 membered heterocyclic groups; Preferably, ring B is a 5-6 membered heteroaryl group containing 1-3 nitrogen atoms.

19. The compound of claim 18 or its stereoisomers, or pharmaceutically acceptable salts, characterized in that, Ring B is selected from Preferably, ring B is 20. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-19, characterized in that, Structural unit Selected from 21. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-20, characterized in that, Ring C is selected from C 4-8 cycloalkyl and C 6-10 Aryl, cyclic C is optionally replaced by R 1a The substitution, preferably, involves the ring C selected from cyclohexyl and phenyl, and the ring C is optionally replaced by R. 1a replace.

22. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-21, characterized in that, R 1a It is a methyl group, or two R atoms attached to the same atom. 1a It cyclizes to a cyclopropyl group.

23. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-22, characterized in that, When R1 and R4 are cyclic with the atoms they are connected to, the structural unit Selected from 24. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-23, characterized in that, When R1 and R4 are decycliced ​​along with the atoms they are connected to, the structural unit... Selected from Preferred structural unit for Further preferred structural units for 25. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-24, characterized in that, Ring D is a 5-6 membered heterocyclic group, preferably a morpholine ring, for example...

26. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-25, characterized in that, Ring E is selected from phenyl, 5-6 membered heterocyclic and 5-6 membered heteroaryl, preferably, ring E is selected from 27. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-26, characterized in that, Structural unit Selected from For example or structural unit Selected from For example 28. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-26, characterized in that, Structural unit Selected from 29. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-28, characterized in that, Ring F is selected from 5-8 membered heterocyclic groups, preferably, ring F is selected from 30. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-28, characterized in that, Ring F and The formed ring structure is selected from 31. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-14, 16-28, characterized in that, Ring G is selected from 5-8 membered heteroaryl, 5-8 membered heterocyclic and C 5-8 Cycloalkenyl, cycloG optionally replaced by R 5a Replacement, preferred, ring G selected from Ring G can be arbitrarily selected by R 5a replace.

32. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-14, 16-28, characterized in that, Ring G and The formed ring structure is selected from Ring G can be arbitrarily selected by R 5a Replacement; preferably, ring G and The formed ring structure is Ring G can be arbitrarily selected by R 5a replace.

33. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-14, 16-28, and 31-32, characterized in that, R 5a Selected from C 3-6 cycloalkyl, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 2-4 alkynyl group, C 1-4 Haloalkoxy, -NR 5aa R 5ab Hydrogen and deuterium, or two R atoms bonded to the same carbon atom. 5a Together with the connected carbon atoms, they form C 3-6 cycloalkyl, wherein R 5aa and R 5ab Each is independently selected from hydrogen and C. 1-4 alkyl; Preferred, R 5a Selected from C 3-6 cycloalkyl and C 1-3 alkyl; Further preferred, R 5a C 1-3 alkyl.

34. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in claim 33, characterized in that, R 5a Selected from cyclopropyl, methyl, ethyl, 1,1,1-trifluoroethyl, -OCH3, -CH2CF3, -CH(CH3)2, -C≡CH, -N(CH3)2, -CH2OH、 -OCHF2, CF3, hydrogen, deuterium, -OCH2CH3 and -NHCH3, or two Rs attached to the same carbon atom. 5a Together with the connected carbon atom, they form a cyclopropyl group; Preferred, R 5a Selected from cyclopropyl, methyl, and ethyl; Further preferred, R 5a It is an ethyl group.

35. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-14, 16-28, and 3134, characterized in that, Ring G and The structural units formed are selected from Preferred Further optimization Where R 5a As defined in any one of claims 1-14, 16-28, 31-34.

36. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-28, characterized in that, Ring H is selected from 5-8 membered heterocyclic groups and C 5-8 Cycloalkenyl, cyclic H optionally replaced by R 6a The preferred alternative is that ring H is selected from... Ring H is arbitrarily assigned to R 6a replace; And / or, R 6a Selected from C 1-6 Alkyl and C 3-6 cycloalkyl, or R attached to the same carbon atom 6a The carbon atoms bonded to it together form C 3-6 Cycloalkyl.

37. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-28, characterized in that, B-ring, H-ring and The formed ring structure is selected from Ring H is arbitrarily assigned to R 6a replace; And / or, R 6a Selected from methyl, ethyl, isopropyl, and cyclopropyl, or R groups attached to the same carbon atom. 6a The carbon atoms connected to it together form a cyclopropyl group.

38. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-14, 16-37, characterized in that, Ring K is selected from 39. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-14, 16-38, characterized in that, Ring K and The formed ring structure is selected from 40. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-39, characterized in that, Ring M is selected from 41. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-40, characterized in that, Ring M and The formed ring structure is selected from 42. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-41, characterized in that, Ring M, The ring system structure formed with ring B is selected from 43. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-42, characterized in that, L3 is selected from -(CH2)3-, -(CH2)4-, -(CH2)2O(CH2)-, -(CH2)O(CH2)2- and -(CH2)2O(CH2)2-.

44. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-43, characterized in that, The compounds are selected from the following structures: Among them, M1, M2, M3, R4, R5, R7, R8, R 1a Rings A, B, C, D, E, F, G, H, K, M, L, L1, L2, m, n, p, and L3 are as defined in any one of claims 1-43, wherein rings A, B, C, D, E, F, G, H, K, and M are optional substitutions; In formula (IQ), R8 is a substituent at any site on ring B1 or ring B2; Ring B1 is a 5-membered heteroaryl group, preferably with N heteroatom, and the number of heteroatoms is 1, 2 or 3. Ring B2 is a 7-membered monocyclic heterocyclic group; Preferred, for 45. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in any one of claims 1-44, characterized in that, The compound has the following structure: Among them, R4, R 5a Ring B, R8, and n are as defined in any one of claims 1-44.

46. ​​The compound of claim 45 or its stereoisomers, or pharmaceutically acceptable salts thereof, characterized in that, The compounds are selected from the following structures: R4, ring B, R8, and n are defined as in claim 45.

47. The compound or its stereoisomer, or a pharmaceutically acceptable salt, as described in claim 46, characterized in that, The compounds are selected from the following structures: R4, R8, and n are defined as in claim 46.

48. A compound or its stereoisomers, or pharmaceutically acceptable salts, characterized in that, The compound is any one of the following compounds:

49. A pharmaceutical composition comprising the compound of any one of claims 1-48 or a stereoisomer thereof, a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier.

50. Use of the compound or stereoisomer of any one of claims 1-48, a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 49 in the preparation of a medicament for treating cancer.

51. Use of the compound or stereoisomer of any one of claims 1-48, a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 49 in the preparation of a medicament for treating PLK4-mediated cancer.

52. The use as described in claim 50 or 51, wherein the cancer is selected from lung cancer, small cell lung cancer, non-small cell lung cancer, breast cancer, colon cancer, brain cancer, pharyngeal cancer, nasopharyngeal cancer, oropharyngeal cancer, head and neck cancer, neuroblastoma, prostate cancer, melanoma, glioblastoma multiforme, ovarian cancer, cervical cancer, lymphoma, leukemia, sarcoma, cancer with tumor effects, osteosarcoma, germ cell tumor, glioma or mesothelioma, soft tissue cancer, neuroblastoma, and liver cancer.

53. A compound or its stereoisomers, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from: in, X is a halogen, selected from fluorine, chlorine, bromine, and iodine; Each PG1 group is independently protected by either hydrogen or amino groups; R x Each is either hydrogen or C. 1-4 alkyl.

54. The compound of claim 53 or its stereoisomers, or pharmaceutically acceptable salts thereof, wherein the compound is selected from: in, PMB stands for 4-methoxybenzyl protecting group.

Images